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Abstract
Kaposi’s sarcoma (KS), an enigmatic endothelial cell vascular neoplasm, is characterized by the proliferation of spindle
shaped endothelial cells, inflammatory cytokines (ICs), growth factors (GFs) and angiogenic factors. KSHV is etiologically
linked to KS and expresses its latent genes in KS lesion endothelial cells. Primary infection of human micro vascular
endothelial cells (HMVEC-d) results in the establishment of latent infection and reprogramming of host genes, and
cyclooxygenase-2 (COX-2) is one of the highly up-regulated genes. Our previous study suggested a role for COX-2 in the
establishment and maintenance of KSHV latency. Here, we examined the role of COX-2 in the induction of ICs, GFs,
angiogenesis and invasive events occurring during KSHV de novo infection of endothelial cells. A significant amount of
COX-2 was detected in KS tissue sections. Telomerase-immortalized human umbilical vein endothelial cells supporting KSHV
stable latency (TIVE-LTC) expressed elevated levels of functional COX-2 and microsomal PGE2 synthase (m-PGES), and
secreted the predominant eicosanoid inflammatory metabolite PGE2. Infected HMVEC-d and TIVE-LTC cells secreted a
variety of ICs, GFs, angiogenic factors and matrix metalloproteinases (MMPs), which were significantly abrogated by COX-2
inhibition either by chemical inhibitors or by siRNA. The ability of these factors to induce tube formation of uninfected
endothelial cells was also inhibited. PGE2, secreted early during KSHV infection, profoundly increased the adhesion of
uninfected endothelial cells to fibronectin by activating the small G protein Rac1. COX-2 inhibition considerably reduced
KSHV latent ORF73 gene expression and survival of TIVE-LTC cells. Collectively, these studies underscore the pivotal role of
KSHV induced COX-2/PGE2 in creating KS lesion like microenvironment during de novo infection. Since COX-2 plays
multiple roles in KSHV latent gene expression, which themselves are powerful mediators of cytokine induction, anti-
apoptosis, cell survival and viral genome maintainence, effective inhibition of COX-2 via well-characterized clinically
approved COX-2 inhibitors could potentially be used in treatment to control latent KSHV infection and ameliorate KS.
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Introduction
KSHV, the most recently discovered human tumor virus, is
etiologically associated with Kaposi sarcoma (KS), primary
effusion lymphoma (PEL) and multicentric Castleman’s disease
(MCD) [1,2]. KS, an AIDS defining condition, is a highly
disseminated unusual angiogenic tumor of proliferative endothelial
cells and displays a very strong resemblance to chronic
inflammation [1,2,3,4]. KS is responsible for significant morbidity
and mortality in HIV-infected patients in the developing world
[1,2]. KS lesions are characterized by proliferating spindle shaped
endothelial cells, neo-vascular structures, inflammatory cells, and
an abundance of inflammatory cytokines (ICs), growth factors
(GFs), angiogenic factors and invasive factors such as basic and
acidic fibroblast growth factor (bFGF, aFGF), interleukin-1a and b
(IL-1a and -1b), granulocyte-monocyte colony stimulating factor
(GM-CSF), platelet derived growth factor b (PDGF-b), vascular
endothelial growth factor (VEGF), interferon-c (IFNc), interlukin
6 (IL-6), tumor necrosis factor a (TNF-a) [2], angiopoietin-2
(Ang2) [5], angiogenin [6], heme oxygenase-1 (HO-1) [7],
transforming growth factor b (TGF-b) [8], adhesion molecules
like inter-cellular adhesion molecule 1 (ICAM-1) and vascular cell
adhesion molecule-1(VCAM-1), and matrix metalloproteinases
(MMPs) like MMP-1, -2, -3, -9, and -19. Cell cultures composed of
characteristic spindle-shaped tumor cells have been established
from KS lesion explants by the addition of cytokines like TNF-a,
TNF-b, IFN-c, IL-1, IL-6, GM-CSF and oncostatin M [1,2,9,10]
highlighting the role of these paracrine factors in KS lesion cell
survival. A crucial step in KS progression is its striking
neovascularization and angiogenesis, which is regulated by
aberrant production of angiogenic and anti-angiogenic factors
from the infected host cells, uninfected neighboring cells or both
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progression are predominantly driven by both paracrine and
autocrine mechanisms, where KSHV infection could induce an
angiogenic, GFs-, and MMPs- rich microenvironment and a
strong cytokine network. These events, via their synergistic actions
and communications, could support continued proliferation and
migration of KSHV latently infected cells [2,12].
KSHV encodes ,86 putative open reading frames (ORFs) of
which at least 22 are potentially immuno-modulatory and anti-
apoptotic [13,14]. Among these are the genes ‘‘pirated’’ from the
host or cellular homologues like viral G-protein-coupled receptor
(vGPCR), vIL-6, viral interferon regulatory factors (vIRFs 1-4),
viral chemokines (vCCLs 1-3), MHC class I down-regulating E3
ligases K3 and K5 (MIR1 and MIR2), and Kaposin B
[13,14,15,16,17,18,19]. These proteins are capable of regulating
cellular cytokine expression, antagonizing host IFN mediated anti-
viral responses and immune evasion, thus suggesting the
importance of ICs in KSHV-associated pathogenesis [20]. In KS
lesion endothelial cells, KSHV is in a latent form with about 10–20
copies of the viral episome per cell and lytic replication is observed
in a low percentage of infiltrating inflammatory monocytes. Low
percentages of KSHV-infected cells in KS lesions are typical
spindle cells which are thought to represent neoplastic cells in these
lesions and these cells occassionaly express lytic gene products,
undergo lytic reactivation and may support productive replication
[21]. During latency, KSHV expresses a battery of genes such as
ORF73 (LANA-1), ORF72 (vCyclin), ORF71 (K13/vFLIP), and
ORFK12 (Kaposin A, B and C), as well as 12 distinct miRNAs.
These gene products obviously must be facilitating the establish-
ment of lifelong latency in its host and in survival against the host
intrinsic, innate and adaptive immune surveillance mechanisms
[22,23,24].
Cytokines have been shown to play important roles in viral
immune evasion and lytic replication. ICs like IL-1b, IL-6, and
TNF-a have been shown to inhibit KSHV lytic gene transcription
in endothelial cells [20]. Host immune responses against KSHV
control viral replication and viral spread and exert a selective
pressure on the virus to establish a latent state which allows the
virus to evade the subsequent wave of adaptive immune host
responses following an effective innate immune response. There-
fore, studying KSHV infection linked cytokines is relevant to
understand viral multifactor patho-biology, its mechanisms to
induce neoplasia, and for developing therapeutic interventions.
Apart from viral genes, this virus has also evolved strategies to
regulate host gene expression to create a microenvironment that is
conducive for viral persistence. One of the host genes that is highly
induced upon de novo infection of human microvascular
endothelial cells (HMVEC-d) and human foreskin fibroblast
(HFF) cells is cyclooxygenase-2 (COX-2) [25,26]. KSHV-encoded
early lytic-cycle membrane protein vGPCR and cell–cell contact
deregulator protein K15 have also been shown to trigger COX-2
induction [27,28]. COX, the rate limiting enzyme of prostaglan-
din synthesis has three isoforms identified to date, namely COX-1,
COX-2, and COX-3. COX-1 is constitutively expressed and
displays characteristics of a housekeeping gene in most tissues. In
contrast, COX-2 is a key enzyme for prostanoid biosynthesis
[29,30]. COX-2 possesses pro-angiogenic, anti-apoptotic proper-
ties and is up-regulated by mitogenic and inflammatory stimuli
[29,30]. COX-2 has also been implicated in the progression and
angiogenesis of several cancers [30,31], and is widely regarded as a
potential pharmacological target for preventing and treating
malignancies [31,32,33].
In our earlier studies, we demonstrated robust COX-2 gene
expression and high levels of PGE2 secretion by KSHV during
primary infection of HMVEC-d and HFF cells [26]. Inhibition of
COX-2 by NS-398 and indomethacin (Indo) did not affect KSHV
binding, internalization of virus, or it’s trafficking to the infected
cell nuclei [26]. Intriguingly, latent ORF73 promoter activity and
gene expression were significantly reduced by COX-2 inhibitors,
and this inhibition was relieved by exogenous supplementation
with PGE2 [26]. In contrast, lytic ORF50 gene expression and
ORF50 promoter activity were unaffected indicating that KSHV
has evolved to utilize COX-2 mediated inflammatory responses
induced during infection of endothelial cells for the maintenance
of viral latent gene expression [26].
Since COX-2 is linked to inflammation and KS is a chronic
inflammation associated malignancy, we hypothesized that COX-
2 is one of the virus’s triggered pathogenic factors with key roles in
inflammation, neo-angiogenesis, cell proliferation, and invasion
associated with the KS lesions. When we tested this hypothesis by
using chemical inhibitors of COX-2 or by COX-2 silencing, we
uncovered evidence for the role of COX-2/PGE2 in viral latent
gene expression, in pro-inflammatory, angiogenic and invasive
events occurring during KSHV de novo infection of endothelial
cells as well as the survival of latently infected endothelial cells.
Effective reduction in secretion of autocrine and paracrine factors
involved in KSHV pathogenesis during early and later time points
of infection, along with cell cycle arrest observed in latently
infected endothelial cells, suggested that COX-2 inhibition based
therapy might provide an effective way to treat the angio-
proliferative KS lesions.
Materials and Methods
Cells
HMVEC-d (CC-2543; Lonza Walkersville, Maryland) were
cultured in endothelial basal medium 2 (EBM-2) with growth
factors (Lonza Walkersville). HEK 293T (human embryonic
kidney cells stably expressing SV40 large T-antigen) cells were
grown in Dulbecco’s modified Eagle’s medium (Gibco BRL,
Grand Island, New York) supplemented with 10% heat-inactivat-
Author Summary
Kaposi’s sarcoma associated herpes virus (KSHV), with a
160 kb DNA genome, has evolved with two distinct life
cycle phases, namely latency and lytic replication. KS, a
complex angioproliferative disease, is regulated by a
balance between pro-angiogenic and anti-angiogenic
factors. In our previous study, we showed that KSHV
modulates host factors COX-2/PGE2 for its own advantage
to promote its latent (persistent) infection. The premise
that COX-2 is involved in growth and progression of
several types of solid cancers and inflammation associated
diseases has been well documented but has never been
studied in KS. Here, utilizing COX-2 inhibition strategies,
including chemical inhibition and a gene silencing
approach, we systematically identified the potential role
of KSHV induced COX-2/PGE2 in viral pathogenesis related
events such as secretion of inflammatory and angiogenic
cytokines, MMPs and cell adhesion in de novo infected or
latently infected endothelial cells. We report that COX-2/
PGE2 inhibition down-regulates viral latent gene expres-
sion and survival of latently infected endothelial cells. The
data emanating from our in vitro studies is valuable,
informative and requires further examination using an in
vitro angiogenic model and in vivo nude mice model to
further validate COX-2 as a novel therapeutic to target
latent infection and the associated diseases like KS.
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and antibiotics [26,34,35]. HUVECs (Lonza Walkersville) were
cultivated in EGM-2 (Lonza Walkersville). Cells were typically
used between 5 to 7 passages. TIVE (telomerase-immortalized
human umbilical vein endothelial) and TIVE-LTC (long-term-
infected TIVE) cells (a gift from Dr. Rolf Renne, Department of
Molecular Genetics and Microbiology, University of Florida) were
cultured in EBM-2 with growth factors. All cells were cultured in
LPS-free medium. All stock preparations of purified KSHV were
monitored for endotoxin contamination by standard Limulus assay
(Limulus amebocyte lysate endochrome; Charles River Endosafe,
Charleston, S.C.) as recommended by the manufacturer [26]. The
COX-1 and COX-2 inhibitor Indomethacin and the COX-2-
specific inhibitor NS-398 [N-(2-cyclohexyloxy-4-nitrophenyl)-
methanesulfonamide] were purchased from Calbiochem, La Jolla,
Calif. Both inhibitors were reconstituted in dimethyl sulfoxide
(DMSO) and DMSO was used as solvent control for all
experiments involving treatments with inhibitors.
Virus
Induction of the KSHV lytic cycle in BCBL-1 cells, supernatant
collection, and virus purification procedures were described
previously [26]. KSHV DNA was extracted from the virus, and
the copy numbers were quantitated by real-time DNA PCR using
primers amplifying the KSHV ORF 73 gene as described
previously [26,34,35].
Lentivirus production and transduction of HMVEC-d cells
Lentiviral constructs expressing shRNAs against human COX-2
and control laminA/C were generated as described [36]. These
shRNA transcription products are known to be processed by the
cell to produce the functional siRNA sequence. AACTGCTCAA-
CACCGGAAT (si-COX-2-1) and CACCATCAATGCAAGT-
TCT (si-COX-2-2) sequences were used as COX-2 shRNAs.
Testing for reduction by shRNA constructs was done by
transfection of target plasmids and shRNA lentiviral construct
plasmids into 293T cells followed by protein extraction and
immunoblot analysis to select the best candidates. Third
generation lentiviral vectors were produced using a four-plasmid
transfection system as previously described [36]. Briefly, 293T cells
were transfected with vector and packaging plasmids. Culture
supernatant was harvested 2 and 3 days post-transfection. Cell
debris from the supernatant was cleared by filtration through 0.22-
mm filters, concentrated by ultracentrifugation, and lentiviral
vector titers were estimated by flow cytometery (eGFP expression).
HMVEC-d cells were transduced with either si-COX-2 or si-lamin
(si-C) to produce si-COX-2-HMVEC-d or si-C-HMVEC-d.
Gene expression profiling by quantitative real time-PCR
Total RNA was converted to cDNA, relative abundance of
target gene mRNA was measured by qRT-PCR using the delta-
delta method (ratio, 2
2[DCt sample–DCt control]) as decribed previously
[37]. Primer sequences are given in Table S2. PCR amplifications
without cDNA were performed as negative controls.
Immunofluorescence assay (IFA)
Confluent HMVEC-d cells in eight-well chamber slides (Nalge
Nunc International, Naperville, Il.) were either uninfected or
infected (30 DNA copies/ cell) for 24h. For COX-2 and VEGF-A
immunostaining, cells were fixed with 4% paraformaldehyde
(PFA), permeabilized with 0.4% Triton-X 100 and stained with
anti-COX-2 goat polyclonal antibody (Cayman chemical, Ann
Arbor, Mich.) and anti-VEGF-A monoclonal antibody (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) overnight at 4uC. Cells
were washed and incubated with 1:200 dilution of Alexa 594-
coupled anti-mouse antibody or Alexa 488-coupled anti-goat
antibody (Molecular Probes, Eugene, OR) for 1 h at RT. Nuclei
were visualized by using DAPI (Ex358/Em461; Molecular Probes)
as counter stain. Stained cells were washed and viewed with
appropriate filters under a fluorescence microscope with the Nikon
metamorph digital imaging system. HMVEC-d cells were either
uninfected or infected (30 DNA copies/ cell) for 2 h, 4 and 5 days
and stained for KSHV latency protein ORF73 (5d) and lytic
protein ORF59 (2 h, 4d and 5d) using antibodies generated in
Prof. Bala Chandran’s laboratory. TIVE and TIVE-LTC cells
were also co-stained for ORF73 and COX-2 using the above
mentioned procedures.
Immunohistochemistry
Sections from lymph nodes and skin biopsy samples of healthy
subjects and KS+ patients were obtained from the AIDS and
Cancer Specimen Resource (ACSR). Sections were deparaffinized
with Histochoice clearing reagent and hydrated with water before
microwave treatment in 1 mmol/l EDTA (pH 8.0) for 15 min for
antigen retrieval, and then blocked with blocking solution (2%
donkey serum, and 0.3% Triton X-100 in PBS). Sections were
incubated with the primary antibodies against COX-2 (Cell
signaling technology Inc.) or ORF73 (generated in Prof. Bala
Chandran’s laboratory) overnight at 4uC. These sections were
incubated with rat-polymer-HRP (Biocare medical) for 15 min,
washed and developed using DAB reagent (DAKO). Counter-
staining was done by hematoxylin. Similar procedure was followed
for COX-2 staining of ACSR KS Screening tissue microarray
(TMA) 09-1 (Table S1).
Immunofluorescence staining of paraffin embedded
tissue sections
Sections from lymph nodes and skin biopsy samples of KS+
patients and control samples were deparaffinized and hydrated
with water before antigen retrieval using DAKO target retriever
solution in steamer for 20 min. Slides were cooled, rinsed, blocked
using 1% BSA in 0.025% Triton X-100-PBS for 30 min and used
for double staining of COX-2 and monoclonal mouse anti-human
CD31 (DAKO, Denmark). Sections were washed and incubated
with 1:200 dilution of Alexa 594-coupled anti-mouse antibody or
Alexa 488-coupled anti-rabbit antibody (Molecular Probes) for 1h
at RT. Nuclei were visualized using DAPI and stained cells were
viewed under an Olympus Confocal laser scanning microscope
(Fluoview FV10i).
Cytokines and Matrix-metalloproteinase (MMP) analysis
Conditioned medium was obtained from serum-starved,
untreated, Indo, NS-398-pretreated HMVEC-d, si-COX-2-
HMVEC-d or si-C-HMVEC-d cells either uninfected or KSHV
(30 DNA copies/ cell) infected for different time points.
Conditioned media were spun at 1,000 rpm for 109 at 4uCt o
remove the particulates and assayed immediately. Total soluble
protein was quantified by bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, IL) prior to use ensuring equal protein
concentration for studying the cytokine profile by human protein
cytokine arrays 3.1 and 5.1 from Ray Biotech (Norcross, GA) and
Ray Biotech human MMP antibody array-1 which detects 10
human MMPs in one experiment. Uninfected HMVEC-d/si-
COX-2-HMVEC-d/si-C-HMVEC-d cells were used as controls
for KSHV infected HMVEC-d/si-COX-2-HMVEC-d/si-C-
HMVEC-d cells, respectively. The cytokine detection membranes
COX-2 in KSHV Biology
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incubated with conditioned media at 4uC overnight. The
membranes were washed, incubated with 1 ml of primary
biotin-conjugated antibody at RT for 2h, washed, incubated with
2 ml of horseradish peroxidase-conjugated streptavidin at RT for
459, and developed using enhanced-chemiluminescence (ECL).
Signal intensities were quantitated using an Alpha Inotech image
analysis system. Signal intensities from all the arrays were
normalized to the same background levels with positive and
negative controls using Ray Biotech human antibody array 3.1/
5.1 and MMP antibody array-1 analysis software.
Matrix-metalloproteinase activity assay
Conditioned media used for the MMP detection by MMP-
antibody array were also used for determination of active/total
MMP-2 and MMP-9 using MMP-2 and MMP-9-enzyme-linked
immunosorbent assay (ELISA) kits from Anaspec (San Jose, CA) as
per manufacturer’s protocols. These kits were optimized to detect
levels of total MMPs and their activities using a 5-FAM/
QXL
TM520 FRET peptide as substrate with its fluorescence
monitored at Ex/Em=490 nm/520 nm upon proteolytic cleav-
age. These novel assays use FRET substrates that incorporate
QXL
TM520 non-fluorescent dyes, the best quencher available for
5-FAM and are designed for the specific quantitation of the
activity of a particular MMP in a mixed biological sample, which
may contain multiple MMPs. A monoclonal anti-human-MMP
antibody was used to pull down both the pro- and active- forms of
an MMP from the mixture, and proteolytic activity quantitated
using a 5-FAM/QXL
TM520 FRET peptide. Similarly, active/
total MMP-2 and MMP-9 levels were detected in the conditioned
media obtained from TIVE cells and COX inhibitor pretreated or
untreated TIVE-LTC cells.
Vascular endothelial growth factor -A and -C protein
measurement
Conditioned medium, obtained as described was used for
quantitating VEGF-A and -C levels using QuantiGlo ELISA kits
(R and D Systems, Minneapolis, MN) as per procedures
recommended by the manufacturer. Each sample was run in
duplicate and the assay repeated a minimum of three times.
Quantities of VEGF-A or VEGF-C released were normalized by
protein content.
ELISA for PGE2 detection
Levels of PGE2 in the supernatants of uninfected and KSHV
infected HMVEC-d cells, and inhibitor treated or COX-2/lamin
silenced and then uninfected or KSHV infected HMVEC-d cells,
or TIVE and TIVE-LTC, COX inhibitor treated or untreated
TIVE-LTC cells were measured by ELISA (Cayman Chemicals)
according to the manufacturer’s instructions [26]. Data are
expressed as the amount of PGE2 produced (pg/ml) per 10
5 cells.
In vitro capillary tube formation assay
Conditioned media were collected from the variously treated
cells for analysis on matrigel and the assay was performed as per
manufacturer’s instructions (BD Biosciences, Mountain View,
CA). Briefly, 5610
4 HUVEC or HMVEC-d cells were plated on a
Matrigel-coated 96-well plate with medium alone or medium
obtained from cells treated with inhibitors alone or cells pretreated
with inhibitors and then KSHV (30 DNA copies/ cell) infected or
the cells silenced for COX-2 and then infected for 24 h. After 16 h
in 5% CO2 at 37uC, the plate was examined for capillary tube
formation under an inverted microscope and photographed. Each
assay was done in duplicate and each experiment was repeated
three times. Angiogenic index, a measure of tube formation, was
calculated based on the number of branch points formed from
each node per field at 10X original magnification. Differences
between the numbers of tube formations in 3D-conditioned
Matrigel assays were subject to student’s t-test analysis. Similar
assay was performed using the conditioned media obtained from
24 h serum starved TIVE cells and COX inhibitors or solvent
pretreated or untreated TIVE-LTC cells.
Western blot analysis
Cell extracts were quantitated by BCA protein assay, then equal
amounts of protein (20 mg/lane) were separated on SDS-PAGE,
electrotransferred to 0.45-mm nitrocellulose membranes. The
membranes were blocked with 5% BSA, probed with anti-
COX-2, active-Rac, total-Rac , b-actin and tubulin antibodies and
visualized using an ECL detection system [26].
Cell adhesion assay
Maxisorp II Nunc ELISA plates (Roskilde, Denmark) were
coated with fibronectin (5 mg/ml), or poly-lysine (2.5 mg/cm
2)
overnight at 4uC and adhesion assays were performed. Briefly,
HMVEC-d cells were resuspended in serum-free EBM-2 medium
and plated at 3610
4 cells in 200 ml/well and incubated at 37uCi n
a5 %C O 2 with 100% humidity. At given times, unattached cells
were removed by rinsing the wells with warm (37uC) PBS.
Attached cells were fixed in 4% PFA, stained with 0.5% crystal
violet and quantified by reading OD at 595 nm.
RhoA and Rac1-GTPase activity by G-LISA activation assay
This assay is based on the principle that a Rho and Rac-GTP-
binding protein is linked to the 96-well plates (RhoA and Rac-1
GLISA from Cytoskeleton, Inc.). The active GTP-bound Rho or
Rac-1 in the cell lysates binds to the wells, while the inactive GDP-
bound Rho or Rac-1 is removed during the washing steps. The
bound active RhoA or Rac-1 is detected with a RhoA or Rac-1
specific antibody and quantitated by absorbance. The degree of
RhoA or Rac-1 activation is determined by comparing readings
from lysates prepared from various treatments.
Invasion assays
Invasion through the extracellular matrix (ECM), an important
step in KSHV pathogenesis, was measured by two methods. 1)
Innocyte cell invasion assay was used to quantitate the invasive cells
and is based on the principle that invasive cells would degrade the
laminin layer and will migrate through the membrane and attach
to the underside of the membrane. These invasive cells are
dislodged from the underside of the cell culture insert and stained
with a fluorescent dye in a single step and fluorescence is
determined using a fluorimeter (Ex485/Em520 nm). Briefly, the
upper chambers of Transwells (Corning Costar) precoated with
ECMatrix was allowed to wet by incubating with serum free EBM-
2. After an hour of hydration, 5610
4 cells (HMVEC-d, TIVE,
TIVE-LTC or HMVEC-d cells treated with various conditioned
media) were plated in the upper chambers. The lower chambers
contained complete growth medium. The inserts were incubated
for 24 h and the invading cells were quantitated by fluorimetry. 2)
Chemicon cell invasion assay was performed to further confirm the
invasion of cells upon various treatments and the assay is based on
staining the invasive cells on the lower surface of the membrane by
dipping inserts into the staining solution, washing, drying the
inserts and counting the cells by photographing the membrane
through the microscope as described in the manufacturer’s
COX-2 in KSHV Biology
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regulating the invasive potential of HMVEC-d, TIVE and TIVE-
LTC cells. Human fibrosarcoma (HT-1080) cells with high
invasive potential were used as positive control.
Cell number and viability assays
The in vitro effects of COX-2 inhibition, serum withdrawl on
TIVE and TIVE-LTC cell numbers, and viability were deter-
mined by traditional trypan blue staining (evaluation of cell
membrane integrity) in quadruplicate. As trypan blue staining is
not a sensitive method for quantitation, the number of viable cells
with their metabolically active mitochondria (an index of cell
proliferation) was also determined by the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT)–based colorimetric
assay (ATCC, Manassas, VA) as per the manufacturer’s
instructions. The MTT assay detects living but not dead cells
and signal generated depends upon the degree of activation of
these cells. Briefly, 0.5610
5 HMVEC-d, TIVE, and TIVE-LTC
cells were allowed to grow in the presence of complete growth
medium (EGM-2) or in basal medium without growth factors and
serum (EBM-2) or EGM-2 containing the indicated amount of
COX-inhibitor or solvent control for 24 h, 48 h, 72 h and 96 h.
10 ml of MTT Reagent was added to all the cells at the indicated
time of treatment and further incubated for 4 h (development of
insoluble purple precipitate), solubilized in detergent and then
read at 570 nm. The amount of MTT (yellow tetrazolium salt),
which is converted to insoluble purple formazan crystals represents
the number of viable cells and the degree of conversion was
assessed by measuring the absorbance at a wavelength of 570 nm.
Cell cycle analysis by flow cytometry
TIVE or TIVE-LTC cells were either untreated or treated with
drugs (Indo or NS-398) or solvent control as described for cell
number and viability assays. Harvested cells were diluted to
contain ,10
6 cells/ml and DNA distribution analysis was
performed. Cells were fixed with 70% ethanol overnight and
DNA was stained with propidium iodide at a final concentration of
50 mg/ml with RNaseA (100 U/ml) prior to flow cytometry
analysis using a LSRII (BD Biosciences). Data were analyzed using
ModFit Lt V3 software (Verity Software House).
Results
COX-2 is expressed in KS lesions
Despite clinical and epidemiological differences, the classic,
epidemic (acquired immunodeficiency syndrome-associated KS),
endemic and post-transplantation associated KS lesions show a
similar histopathology characterized by spindle shaped endothelial
cells with latent KSHV infection expressing endothelial markers
(CD31, CD34, CD36, and EN4), extensive neo-angiogenesis and
inflammatory infiltration [21,38,39,40]. We analyzed the skin and
lymph node tissue sections of healthy subjects and KS+ patients
obtained from ACSR for the presence of COX-2 with anti-COX-
2 antibody. Normal healthy control tissue sections (Figure 1A,
panel 1) and normal healthy lymph node sections (Figure 1A,
panel 5) showed negligible expression of COX-2. In contrast,
abundant COX-2 expression was detected in KS skin tissue
(Figure 1A, panel 2; Figure S1) and KS lymph node section
(Figure 1A, panel 6; Figure S1). Intense, patchy COX-2 expression
was detected in KS lymph node sections, especially surrounding
neovascular structures (Figure 1A, panels 6 and 7; Figure S1). KS
skin tissue and lymph node sections showed distinct nuclear
staining for KSHV latency associated LANA-1 (ORF73) protein
(Figure 1A, panels 4 and 8; Figure S1). Specificity of COX-2
staining was confirmed by the non-reactivity of isotype control for
COX-2 antibody (Figure 1A, panel 12). Cytoplasmic COX-2
staining was observed in KS skin tissue sections, which were also
observed in cells showing spindle phenotype (Figure 1A, panels 3
and 11). Strong COX-2 staining was also observed in the lining of
neovascular structures in KS patient lymph nodes (Figure 1A,
panels 6, 7, 9 and 10). We next assessed the phenotype of spindle
cells for endothelial marker CD31 as well as COX-2. CD31 (red)
was detected in spindle cells of KS lesions (Figure 1B, panels 1–6)
and in KS patient lymph nodes (Figure 1B, panels 7–15). KS tissue
sections (skin and lymph nodes) showed many strong CD31-COX-
2 double positive cells (Figure 1B, panels 1–15). Many CD31
positive cells in KS skin tissue (Figure 1B, panels 1–6) and cells
lining the neovascular structures in KS lymph node sections
(Figure 1B, panels 7–15) displayed strong staining for COX-2.
COX-2 (green) staining was not just limited to spindle cells present
in KS tissues but also to other smaller cells whose morphological
appearances suggested that they are most likely macrophages and/
or lymphocytes (Figure 1B, panel 3). Strong COX-2 and CD31 co-
staining was also observed in the lining of KS lymph node
neovascular structures (Figure 1B, panels 7–15).
To define the prevalence of COX-2 up-regulation in KS, COX-
2 staining was performed in KS-TMAs as described in Material
and Methods. Varying level of COX-2 staining was observed in a
variety of tissues from KS patients (Figure S2). Several sections
from skin showed negligible staining (Figure 1C, panels 1 and 2)
whereas the majority of them showed strong patches (Figure 1C,
panels 4 and 5) of COX-2 staining. Very low COX-2 staining was
observed in some sections from mouth (Figure 1C, panel 3). Strong
COX-2 staining was observed in eye orbit (panel 6), tonsil (panel 7)
and mouth (panel 8) and small bowel (panels 9 and 10) sections.
Specificity of COX-2 staining was also confirmed by the non-
reactivity of isotype control for COX-2 antibody even when tested
on the colon cancer tissue (Figure 1C, panel 12) as compared to
staining with COX-2 antibody (Figure 1C, panel 11). To further
demonstrate that all TMA sections did not show strong or some
nonspecific COX-2 staining, we provide some examples of
sections with negligible, low and strong staining for COX-2
(Figure S2). A higher number of sections showed immunoreactivity
for COX-2 but the levels of staining varied among the sections
(Figure S2) suggesting a potential connection between COX-2 and
KS. Magnified view of various KS sections described in Figures 1A
and 1C are given in Figure S1 which clearly demonstrate COX-2
distribution in KS tumor cells with characteristic spindle
phenotype. These results demonstrate that COX-2 is an abundant
factor in the majority of KS lesions with a few exceptions
(Figure 1C, panels 1–3, Table S1), and thereby suggesting that
COX-2 might be playing a key role in KSHV pathogenesis.
De novo KSHV infection induces COX-2 and m-PGES-1 in
endothelial cells
Our previous study demonstrated that de novo infection of
endothelial cells with 10 DNA copies/ cell of KSHV up-regulated
COX-2 during early time points of infection which was
maintained at 2–3 fold even at 72 h PI. Here, we extended this
observation using higher KSHV DNA copies per cell (30) for
infection of HMVEC-d cells and observed the cells until 5d PI.
KSHV ORF73 gene expression as assessesd by qRT-PCR
(Figure 1D) as well as by real-time RT-PCR with ORF73 gene
specific primers and Taqman probes (data not shown) confirmed
the successful infection of these cells. Compared to uninfected cells
at all the respective time points, KSHV infection induced about
49, 44, 24, 15, 17, 15, 11, and 12- fold COX-2 expression at 2 h,
4 h, 8 h, 1d, 2d, 3d, 4d and 5d PI, respectively (Figure 1D). In
COX-2 in KSHV Biology
PLoS Pathogens | www.plospathogens.org 5 February 2010 | Volume 6 | Issue 2 | e1000777Figure 1. COX-2 expression. (A) COX-2 expression in KS tissue. Samples were analyzed by immunohistochemical staining for COX-2 (panels
1–3, 5–7, 9–11), anti-ORF73 (panels 4 and 8) and isotype control antibody alone (panel 12) and counterstained with hematoxylin. Arrow (black) in all
the panels (2, 3, 6, 7, 9, 10 and 11) indicates COX-2 staining. Arrow (white) in panels 4 and 8 indicates ORF73 staining. Magnifications: panels 1, 2, 4–6
and 8: 20X; panels 3, 7, 9–12: 60X. Magnified views are given in Figure S1.( B) COX-2 and CD31 double staining in KS skin and lymph node
sections. Samples were analyzed by immunofluoresence staining for COX-2 and CD31 staining in KS skin (panels 1–6) and lymph node sections
(panels 7–15). Red arrows indicate COX-2 (green) staining (panels 2, 5, 8, 11 and 14). White arrows indicate CD31 (red) staining (panels 1, 4, 7, 10 and
13). White arrow heads indicate areas of COX-2 and CD31 co-staining in the same cells (panels 3, 6, 9, 12 and 15). Yellow arrow heads indicate cells
staining for COX-2 but not CD31 (panels 3, 6, 9, 12 and 15). Yellow arrows depict COX-2 staining cells with no spindle phenotype or endothelial cell
morphology (panel 3). (C) COX-2 expression in various tissues of KS patients. ACSR-KS Screening TMA 09-1 tissue sections had sections from
skin (panels 1, 2, 4 and 5), mouth (panels 3 and 8), eye orbit (panel 6), tonsil (panel 7) small bowel (panels 9 and 10) as well as tongue, anus,
nasopharynx, rectal mucosa, epiglottis, hypopharynx, soft tissue mass, lung and gastric mucosa (Table S1). Brown color indicates COX-2 staining
(panels 1 to 10). Panels 11 and 12 are colon cancer tissue stained with COX-2 antibody or IgG control for COX-2 antibody, respectively. Magnifications:
panels 1–8: 20X; panels 9–12: 60X. (D) Induction of COX-2 and m-PGES-1 during de novo KSHV infection. HMVEC-d cells grown to 80–90%
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1, an enzyme converting PGH2 to PGE2, with about 13, 12.5,
11.3, 13, 10,11, 9, and 7-fold induction at 2 h, 4 h, 8 h, 1d, 2d, 3d,
4d and 5d PI, respectively (Figure 1D). To determine the
percentage of cells expressing latent genes and undergoing
spontaneous KSHV lytic replication, IFA was carried out using
antibodies against ORF73 (latency marker) and ORF59 (proces-
sivity factor and a marker of lytic replication) proteins (Figure S3).
Detection of a few lytic cycle positive cells at early time points (2h)
of KSHV infection could be due to transient lytic burst in primary
endothelial cells [41]. At 5 day PI, about 70–80% of cells stained
positive for nuclear punctate pattern of ORF73 (Figure S3, panels
4 and 6) and about 9–12% stained positive for lytic ORF59 at
early time (2h) (Figure S3, panels 10 and 12), whereas 15–17%
cells displayed lytic cycle activation at later (5d) time point of
infection (Figure S3, panels 16 and 18). We also detected a low
level (8–10%) of lytic induction at 4d post KSHV infection (Figure
S3, panels 13 and 15). The percentage of cells expressing ORF59
at 5d PI was significantly higher than at 4d PI and was
reproducible. The spike of lytic burst at 5d PI in HMVEC-d cells
could also be due to continued presence of pro-IC rich
microenvirnment created by KSHV infection. These infected
cells expressed high copy numbers for early lytic cycle switch
protein ORF 50 at 2h post KSHV infection (data not shown). We
emphasize that all analyses are based on IFA for lytic cycle ORF59
protein and hence, percentage of cells will not be identical for all
endothelial cells (HUVEC cells) and might also depend on the
number of KSHV DNA copies per cell used for infection.
COX-2 is expressed in long term KSHV infected
endothelial cells
TIVE-LTC cells are endothelial cells in culture with tightly
latent KSHV gene expression supporting long-term episomal
maintenance which is similar to viral-gene expression in the
majority of KS lesion spindle cells [42]. KSHV-positive TIVE-
LTC cells expressed very high levels of ORF73 gene expression.
Compared to uninfected TIVE cells, TIVE-LTC cells showed
increased expression of COX-2 (5-fold), m-PGES-1 (4-fold) and
VEGF-A (8-fold) (Figure 2A). Compared to uninfected TIVE
cells, KSHV-positive TIVE-LTC cells showed (4-fold) higher
levels of COX-2 protein (Figure 2B). Punctate nuclear staining of
ORF73 was observed in 50–60% of TIVE-LTC cells (Figure 2C;
Panels 1 and 3). Distinct perinuclear COX-2 staining was
observed in a majority of the TIVE-LTC cells (Figure 2C; Panels
2 and 5). Besides ORF73 positive cells, the majority of
neighboring uninfected cells located in close proximity to the
infected cells were also positive for COX-2 (Figure 2C; Panels 2,
3, 5 and 6). Overall, 70–80% of TIVE-LTC cells were positive
for COX-2. Detection of COX-2 in uninfected cells could be due
to paracrine COX-2 stimulation by the various cytokines and
growth factors induced by KSHV. Similarly, COX-2 expressing
uninfected cells were also seen in KSHV-infected HMVEC-d
monolayer but were distinctly less in number and were in close
proximity to the infected cells (data not shown). Similarly stained
TIVE cells showed very faint cytoplasmic basal staining for
COX-2 in a few cells(Figure 2C; panels8 and 11) and no staining
for viral latent protein ORF73 (Figure 2C; panels 7 and 10).
COX-2 staining in TIVE cells (Figure 2C; panels 8, 9, 11 and 12)
was not comparable to the strong perinuclear COX-2 staining
s e e ni nT I V E - L T Cc e l l s( F i g u r e2 C ;p a n e l s2 ,3 ,5a n d6 ) .
Compared to uninfected TIVE cells, significantly higher levels of
PGE2 (pg/ml) were detected in the supernatants of TIVE-LTC
cells (Figure 2D).
Inhibition of COX-2 reduces KSHV latent ORF73 gene
expression in TIVE-LTC cells
Since COX-2 inhibition down-regulated ORF73 gene expres-
sion during de novo KSHV infection [26], we next determined the
effect of NS-398 and Indo treatment on ORF73 gene expression in
TIVE-LTC cells. First, we determined the concentrations of COX
inhibitors affecting PGE2 secretion. TIVE-LTC cells pretreated
with nontoxic doses of either Indo (500 mM or 250 mM) or NS-398
(50 mMo r7 5mM) at 37uC for 1h did not completely inhibit PGE2
secretion (Figure S4). In contrast, by increasing the incubation
period with these inhibitors to 8 h and 24 h, we observed a
significant reduction (,80%) in PGE2 secretion (Figure S4). This
requirement for a higher dose of inhibitors to block COX-2
function and PGE2 secretion could be due to the continuous loop
of COX activation leading to the maintenance of a constant level
of PGE2 in latently infected cells.
NS-398 and Indo treatment of TIVE-LTC cells for 24 h down-
regulated viral latent (ORF73) gene expression by 48% and 57%,
respectively (Figure 2E). Significant detection of COX-2 in KS
lesions (Figure 1A, B and C), long term KSHV infected endothelial
cells (Figure 2) and in de novo infection of endothelial and
fibroblast cells [26], as well as modulation of viral gene expression
by COX inhibition (Figures 1 and 2), strongly indicated a role for
COX-2/PGE2 in KSHV pathogenesis.
COX-2 silencing reduces COX-2 gene expression and
PGE2 secretion in HMVEC-d cells
Pre-treatment of endothelial cells with chemical nonsteroidal anti-
inflammatory drugs (N SAID) like Indo or COX-2 selective inhibitor
(COXIB) NS-398 prior to KSHVinfection abrogated the secretion of
PGE2 [26]. These conventional NSAIDs have been shown to cause
serious and significant complications [43]. Though the selective
COX-2 inhibitors cause only occasional deleterious effects, they have
also been shown to exhibit some COX-2 independent effects such as
up-regulation of death receptor 5 (DR5) expression, inhibition of
survival signal pathways, and augmentation of apoptosis [43,44]. To
determine the specificity of COX-2 involvement in KSHV
pathogenesis and to avoid COX independent effects of chemical
inhibitors, we used a COX-2 silencing method.
293T cells were co-transfected with COX-2 expression plasmid
and si-COX-2-1, si-COX-2-2 and si-Control (si-C) plasmids.
Transfection with pcDNA was used as a control (Figure 3A, lane
2). Western blots for COX-2 confirmed the silencing of COX-2 by
si-COX-2 (Figure 3A, lanes 3 and 4) compared to si-C (Figure 3A,
lane 1), and tubulin was utilized as a loading control. Co-
transfection of 1 mg COX-2 expression plasmid and si-C showed
10-fold induction of COX-2 protein (Figure 3A, lane1). Transfec-
tion with 1 mg of either si-COX-2-1 or si-COX-2-2 along with
COX-2 expression plasmid showed 85% and 90% reduction in
COX-2 protein levels, respectively (Figure 3A, lanes 3 and 4).
These results clearly implied that COX-2 silencing by these
sequences was effective. We used both the plasmids to generate
confluence were serum starved for 8h and infected with 30 DNA copies/ cell of KSHV. Total RNA from infected and uninfected cells was DNase-1
treated and subjected to q-RT-PCR using ORF73, COX-2 and m-PGES-1 gene specific primers using the DDCt method. Ct value obtained for ORF73 in
uninfected cells (mostly close to non template control) was used for calculating fold inductions. Fold induction was calculated by considering
induction in uninfected cells at respective times as 1-fold. Each bar represents the average 6 SD of three independent experiments.
doi:10.1371/journal.ppat.1000777.g001
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PLoS Pathogens | www.plospathogens.org 7 February 2010 | Volume 6 | Issue 2 | e1000777Figure 2. COX-2 in latently infected TIVE-LTC cells. (A) Expression of COX-2, m-PGES-1 and VEGF-A. TIVE and TIVE-LTC (KSHV) cells were
used to prepare total RNA and the expression of host genes like COX-2, m-PGES-1 and VEGF-A (A) were analyzed using the DDCt method. Fold
induction was calculated by considering expression in TIVE cells as 1-fold. (B) Protein levels of COX-2. Lysates from 24h serum starved TIVE and
TIVE-LTC cells were Western blotted for COX-2, stripped and immunoblotted for tubulin and a representative blot from three independent
experiments is shown. (C) Immunofluoresence analysis of ORF73 and COX-2. TIVE and TIVE-LTC cells were grown to 80–90% confluence,
serum starved for 24 h, fixed, permeabilised and examined with ORF73 (red) and COX-2 (green) specific antibodies. (D) PGE2 secretion.
Conditioned media from 24 h or 48 h serum starved TIVE and TIVE-LTC cells were measured for secreted PGE2 levels using a PGE2 ELISA. (E) Effect of
inhibitors on ORF73 gene expression. TIVE-LTC cells were untreated, solvent control treated or treated with 500 mM Indo or 75 mM NS-398 for
24 h. RNA was isolated and viral transcripts were quantitated. The % inhibition was calculated by considering KSHV-ORF73 gene expression in
untreated TIVE-LTC cells as 100%. Each point represents the average 6 SD from three independent experiments (A, D, and E).
doi:10.1371/journal.ppat.1000777.g002
COX-2 in KSHV Biology
PLoS Pathogens | www.plospathogens.org 8 February 2010 | Volume 6 | Issue 2 | e1000777si-COX-2 lentiviruses which were used throughout this study. The
lentivirus preparations were quantified for their titer and 30 DNA
copies/ cell of all three lentiviruses [si-C, si-COX-2-1 and si-
COX-2-2] were used for transduction in HMVEC-d cells. We
observed very high transduction efficiency (.90% of HMVEC-d
cells expressing GFP) by fluorescence microscopy.
Figure 3. Evaluation of COX-2 siRNA for silencing COX-2. (A) Two constructs, si-COX-2 -1 and si-COX-2-2 expressing siRNAs for COX-2 were
generated. Lysates from 293T cells co-transfected with COX-2 expression plasmid and si-COX-2-1 (lane 3) or si-COX-2-2 (lane 4) or si-C (lane 1) (36 h)
were Western blotted for COX-2, stripped and immunoblotted for tubulin. Lysate prepared from 293T cells transfected with pcDNA alone was used as
control (lane 2). N.S= non-specific band. (B) HMVEC-d cells transduced for 48 h with si-C or si-COX-2-1 or si-COX-2-2 were serum starved for 8 h, and
infected with KSHV for 2, 4, 8 and 24 h or stimulated with TNFa (20 ng/ml) for 309. RNA from these cells was analyzed by q-RT-PCR for COX-2
expression and the supernatants were used to quantify PGE2 concentration by ELISA. Panel B represents the fold induction of COX-2 gene expression
calculated by considering expression in uninfected cells as 1 fold. Similarly, PGE2 levels in quadruplicate samples were measured and values are
presented in pg/ml. % inhibition was calculated by considering COX-2 expression or PGE2 release from the infected cells at the respective time of
measurement as 100%. Data is from four independent experiments. (C) Effect of COX-2 silencing on KSHV ORF73 gene expression. HMVEC-d
cells were transduced with si-C, si-COX-2-1 and si-COX-2-2 and after 48 h, serum starved for 8 h and infected with 30 DNA copies/ cell of KSHV for
24 h. RNA was isolated and treated with DNase I, and 250 ng of DNase-treated RNA was subjected to real-time RT-PCR with KSHV ORF73 gene-
specific primers and TaqMan probes. The relative copy numbers of viral transcripts were calculated using a standard graph generated by using
known concentrations of DNase-1 treated, in vitro-transcribed ORF73 transcripts in real-time RT-PCR and normalized with GAPDH. Each reaction was
done in duplicate, and each point represents the average 6 SD from three independent experiments. The % inhibition was calculated by considering
KSHV-ORF73 gene expression in 24 h infected si-C HMVEC-d cells as 100%.
doi:10.1371/journal.ppat.1000777.g003
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2 gene expression and PGE2 secretion in HMVEC-d cells
Effect of COX-2 silencing in HMVEC-d cells was determined
by infecting serum starved (8 h) si-C, si-COX-2-1 or si-COX-2-2
transduced cells for 2 h, 4 h, 8 h, and 24 h. These cells were
treated with TNF-a for 309 to serve as a positive control for COX-
2 induction. Compared to uninfected si-C cells, KSHV infected si-
C-HMVEC-d cells showed high COX-2 gene expression
(Figure 3B). In contrast, KSHV infected si-COX-2-1 or si-
COX-2-2 -HMVEC-d cells showed significantly reduced COX-2
expression (Figure 3B). Overall, si-COX-2-1 or si-COX-2-2 -
HMVEC-d cells showed 82% and 93% reduction in COX-2
expression, respectively (Figure 3B).
We next assessed the functional consequences of COX-2
silencing by quantifying the secreted PGE2 levels in the
supernatant of KSHV infected lentivirus transduced HMVEC-d
cells (Figure 3B). In si-C-HMVEC-d cells, PGE2 secretion levels
dramatically increased upon KSHV infection. Though there was
induction in PGE2 levels in si-COX-2 transduced cells upon
KSHV infection, this induction was lower than in si-C-HMVEC-d
cells (Figure 3B). Similarly, TNF-a induced PGE2 secretion was
reduced drastically in si-COX-2- HMVEC-d cells (Figure 3B)
suggesting that COX-2 silencing could effectively abrogate KSHV
infection induced PGE2 secretion in endothelial cells. COX-2
silencing did not change COX-1 expression (data not shown)
further validating the specificity of the knock-down procedure.
Silencing of COX-2 reduces KSHV latent ORF73 gene
expression in HMVEC-d cells
We also assessed the consequence of COX-2 silencing on
KSHV latent gene expression (Figure 3C). After 24 h KSHV
infection, we observed about 61% and 59% reduction in ORF73
gene expression in si-COX-2-1 and si-COX-2-2 -HMVEC-d cells,
respectively (Figure 3C). These results supported our earlier
findings in HFF cells with chemical inhibitors [26] and
demonstrated that COX-2 silencing effectively reduced KSHV
latent gene expression.
De novo infection of HMVEC-d cells induces secretion of
pro-inflammatory cytokines
In our earlier studies of oligonucleotide array analysis of KSHV-
infected HMVEC-d and HFF cells at 2 and 4 h PI, we observed
the reprogramming of host transcriptional machinery regulating a
variety of cellular processes, including apoptosis, cell cycle
regulation, signaling, inflammatory response and angiogenesis
[25]. Since COX-2 has also been shown to regulate the majority of
these factors, we next analyzed the role of KSHV-induced COX-2
in the modulation of these factors. Conditioned media (no serum)
collected from KSHV-infected HMVEC-d cells at 2 h, 4 h, 8 h,
24 h, 4 days and 5 days PI were used to study the cytokine profile
(Figure 4). Induction of cytokines was compared to the released
cytokine levels in the uninfected cell supernatant at respective time
points. Compared to uninfected HMVEC-d cells, KSHV infection
triggered an appreciable (1.5-2) fold induction in the secretion of
pro-ICs, such as growth regulated oncogene (GRO), GROa, IL-
1a, IL-1b, ILs- (2,3, 6, 7, and 12-p40), TNF-a, TNF-b and IFN-c
at 4 h PI. 1.5 to 2-fold induction in these cytokine levels further
up-regulated to 3 –3.5 -fold by 8 h, decreased to 2–2.5-fold by
24 h, 1.5–2 -fold at the 4d, and enhanced dramatically to 4–4.5 -
fold at 5d PI (Figure 4, Table S3). Since, we did not observe an
increase in these cytokines released at 2h PI, we used 4, 8 and 24 h
PI time points throughout this study. Among all these cytokines,
IL-8 levels did not increase at 5d PI. The drastic increase in the
cytokine levels observed at 5d PI might be due to the spontaneous
induction of KSHV lytic cycle replication observed in about 15–
17% of these infected cells (Figure S3).
De novo infection of HMVEC-d cells induces secretion of
chemokines
Compared to uninfected cells, KSHV infection induced the
secretion of chemotactic cytokines (chemokines) that mediate
leukocyte recruitment to sites of inflammation, fibrosis, and
malignancy such as RANTES, macrophage chemoattractant
protein-2 (MCP-2), MCP-3, thymus and activation-regulated
chemokine (TARC), macrophage inflammatory protein (MIP-
1D), macrophage derived chemokine (MDC), monokine induced
by IFN-Gamma (MIG), epithelial neutrophil-activating peptide
(ENA-78), and inflammatory cytokine 309 (I-309) (Figure 4B,
Table S3). Among these chemokines, MCP-1 was the only one
that was not up-regulated at all time points tested as the uninfected
cells always showed some level of MCP-1 secretion in the culture
supernatants.
De novo infection of HMVEC-d cells by KSHV induces
secretion of multiple growth and angiogenic factors
KSHV infection stimulated the secretion of growth factors and
angiogenic factors such as insulin-like growth factor-1 (IGF-1),
platelet derived growth factor-BB (PDGF-BB), macrophage colony
stimulating factor (M-CSF), granulocyte colony-stimulating factor
(G-CSF), GM-CSF, angiogenin (Ang), oncostatin-M (Onco-M),
TPO (thrombopoietin), VEGF, stromal cell-derived factor-1 (SDF-
1), SCF (stem cell factor), TGF-b1 and leptin (Figure 4C, Table
S3). EGF (epidermal growth factor) was very highly up-regulated
at the early time points of KSHV infection with about ,4 fold
induction at 2 h PI, which decreased to 1.5-fold by 4 h PI,
increased at 8h to ,3- fold before decreasing to 2- fold by 24h and
4 days, and finally increased at 5 days PI (Figure 4C, Table S3).
Endogenous levels of EGF were high as the supernatants obtained
from uninfected cells also showed higher levels of EGF secreted
(data not shown).
De novo infection of HMVEC-d cells induces secretion of
anti-inflammatory cytokines
Compared to uninfected HMVEC-d cells, KSHV infection
enhanced the secretion of anti-inflammatory cytokines, such as ILs
(24, 25,210, 213 and 215) with 1.5 to 2.5-fold at 4 and 8h PI
which decreased to 2-fold at 4d and was up-regulated at 5d PI
(Figure 4D, Table S3). IL-10 levels were higher than all other anti-
ICs with ,4 fold from 8h PI to 5d PI (Figure 4D, Table S3).
Specificity of KSHV induced cytokine secretion
To evaluate the specificity of KSHV infection induced cytokine
secretion, virus was pre-incubated with 100 mg of heparin/ml
which has been shown to block about 80% of virus binding and
entry into the various target cells [26,35]. Conditioned medium
from serum starved HMVEC-d cells infected for 96h (Figure S5A,
panel 1) showed a significant increase in the levels of various
cytokines and inflammatory molecules, which were greatly
reduced by pretreatment of the virus with heparin (Figure S5A,
panel 2). Representative data from one time point of infection
shows that there was complete inhibition of SDF-1, SCF, TGF-b
and TARC with 60–70% inhibition of GM-CSF, GRO, GRO-a,
ILs (22,23, 24,25, and 210), MDC, MIG, MIP-1D, RANTES,
IGF-1, angiogenin, oncostatin-M, and TPO and 30–40%
inhibition of VEGF, PDGF-BB, IL-7, IL-1b, and IL-8. There
was no detectable inhibition in secretion of MCP-1 and EGF
COX-2 in KSHV Biology
PLoS Pathogens | www.plospathogens.org 10 February 2010 | Volume 6 | Issue 2 | e1000777(Figure S5A, panel 2) which might be due to their high
endogenous levels of secretion even in the uninfected cell culture
supernatant. These results demonstrated that the vast majority of
the observed cytokine induction (Figure 4, A to D) was due to
KSHV infection and not due to LPS or contaminating host cell
factors in the virus preparations.
KSHV induced COX-2 regulates the expression of a
number of KSHV induced cytokines
To understand the role of KSHV induced COX-2 in cytokine
secretion detected in infected HMVEC-d cells, we used COX-2
inhibitors in conjunction with COX-2 silencing methods and
examined cytokine gene expression. We prepared cDNA from
serum starved (8h) cells either infected (4 h, 8 h, 24 h) or
pretreated with either NS-398 (50 mM) or Indo (500 mM) (data
not shown), and then infected with KSHV for 4 h, 8 h, and 24 h.
Similarly, cDNA was prepared from serum starved (8 h) cells
transduced with si-C, si-COX-2-1 or si-COX-2-2 and then
uninfected or infected with KSHV for 4 h, 8 h and 24 h. cDNA
was used for q-RT-PCR to quantitate the fold expression of
specific cytokines, selected based upon our observations from
Figure 4, such as IL-8, VEGF-A, GRO, VEGF-C, IL-1b, GM-
CSF, RANTES, and SDF-1, normalized to the expression of
endogenous HPRT and tubulin genes. Analyses of the results
showed time dependent patterns of inhibition of gene expression
by both methods of COX-2 inhibition (Figures 5 and S6).
In pattern one, KSHV infection induced nearly 5, 5.3, and 6.1-
fold expression of IL-8 gene at 4 h, 8 h and 24 h PI, respectively
compared to uninfected HMVEC-d cells, which were unaffected
by pretreatment of cells with NS-398 for 1 h or by si-COX-2-2.
These results suggested that IL-8 gene expression was not directly
regulated by KSHV induced COX-2 (Figure 5A). In pattern two,
in contrast, both COX-2 inhibitor treatment and COX-2
knockdown reduced KSHV induced VEGF-A and VEGF-C gene
expression significantly at both early and late time points
(Figures 5B and S6A), thus suggesting a role for KSHV induced
COX-2 in the regulation of VEGF-A and -C at all time points of
infection. In pattern three, a significant reduction of IL-1b and
GM-CSF gene expression by COX-2 inhibitor treatment and
COX-2 knockdown was observed at 4 and 8 h PI, and was
moderately less at 24 h PI (Figures 5C and S6B). These results
suggested a role for COX-2 in KSHV induced IL-1b gene
expression at an early time point of infection. In pattern four, the
expression of KSHV induced GRO, RANTES and SDF-1 genes
were not significantly affected by NS-398 and si-COX-2 at 4 h PI,
while significant reductions were observed at 8 and 24 h PI
(Figures S6C, S6D, and 5D). This suggested that COX-2 plays a
role in the regulation of these genes at later time points.
Figure 4. Induction of pro-inflammatory cytokines, chemokines, growth, angiogenic factors, and anti-inflammatory cytokines in
HMVEC-d cells by KSHV infection. Densitometric analysis of cytokine array blots was carried out to determine the differences in the release of
cytokines from serum-starved, uninfected HMVEC-d cells and cells infected with KSHV for 2 h, 4 h, 8 h, 24 h, 4 days and 5 days. The values were
normalized to identical background levels using the Ray-Biotech Array 3.1 analysis tools. The increase in cytokine levels was calculated by dividing the
respective values obtained from infected-cell supernatants with the values obtained from uninfected-cell supernatants and cytokines showing
significant changes with respect to uninfected cells are represented in a line graph format. (A) Pro-inflammatory cytokines; (B) chemokines; (C)
growth and angiogenic factors; (D) anti-inflammatory cytokines.
doi:10.1371/journal.ppat.1000777.g004
COX-2 in KSHV Biology
PLoS Pathogens | www.plospathogens.org 11 February 2010 | Volume 6 | Issue 2 | e1000777Overall, inhibition of cytokine gene expression by COX-2
inhibitor treatment and COX-2 knockdown were comparable.
Both methods inhibited gene expression of VEGF-A, VEGF-C
(angiogenic molecules), GRO (cytokine with inflammatory and
growth-regulatory properties), RANTES (cytokine regulating T
cell response) and SDF-1(a ligand for the chemokine receptor
CXCR4) even at 24 h PI. Inhibition of IL-1b gene expression at
early time points is not due to the inactivation of COX-2 inhibitor
or less inactivation of COX-2 by the silencing method but
demonstrates the specificity of the observed results. Absence of
100% reduction in the expression of the examined cytokine genes
by both methods could be due to the inability to inactivate or
deplete COX-2 completely, paracrine effects of the released
additional factors and/or additional factors besides COX-2 in the
regulation of these genes in KSHV infected cells.
ToexaminetheroleofCOX-2inthesecretionofvariouscytokines
during KSHV infection, we analyzed the cytokines from COX-2
inhibited cells. Data obtained from COX-2 inhibitor pretreatment
followed by infection (4 h, 8 h, 24 h) or cells silenced for COX-2 and
then infected for different time points (4 h, 8 h, 24 h) is presented as
fold reduction compared to signals obtained from untreated KSHV
infected cells, and KSHV infected si-C-HMVEC-d at respective time
points (Table S4). Results shown in Table S4 can be divided into
three groups. Group 1 includes cytokines inhibited by both kinds of
COX-2 inhibition (chemical as well as silencing). Group 2 includes
the cytokines inhibited by chemical inhibitor (NS-398) treatment
alone but not reduced by COX-2 knock-down. Group 3 includes the
cytokines up-regulated by COX-2 inhibition.
Group 1 cytokines are specifically dependent upon COX-2 which
includes: pro-ICs like IL-1 (a and b), ILs (22, 23, 2p40 and 216)
TNFa,I F N c, LIGHT; chemokines including RANTES, MCP-2,
MCP-3, TARC, MIP-1D, ENA-78, I-309, MIF, GCP-2, MIP-3-a,
Eotaxin, Eotaxin-2, Eotaxin-3, IP-10, NAP-2, CK-b8-1; growth and
angiogenic factors including PDGF-BB, MCSF, G-CSF, GMCSF,
angiogenin, oncostatin M, thrombopoeitin, VEGF, SDF-1, SCF,
TGF-b1, Leptin, FGFs (24, 26, 27, 29), Flt3-ligand, Fractalkine,
IGFBPs (22, 23, 24), BDNF, PIGF, HGF (hepatocyte growth
factor), Osteoprotegerin, NT-3, NT-4; and anti-inflammatory
cytokines like IL-4, IL-13, and IL-15. In all these cytokines reported,
although the fold reduction between the inhibitor treatment and
COX-2 silencing were not identical, they were comparable. Overall,
a profound reduction was observed in the levels of ILs (1b, 22,
23,24, 213, 215 216, 2p40), IFNc,M C P s( 22, 23), TARC,
MIP-1D, ENA-78, I-309, GCP-2, Eotaxin, Eotaxin-3, PDGF-BB,
G-CSF, angiogenin, Oncostatin M, TPO, VEGF, SDF-1, SCF,
TGF-b1, Leptin, FGFs (24, 26, 27), Flt3-ligand, Fractalkine,
IGFBP-4, BDNF,PIGF, Osteoprotegerin, NTs (23, 24) (TableS4).
Group2 cytokinesincluding pro-ICs(GRO, GRO-a, IL-6, IL-7,IL-
8, TNFb), chemokines (MCP-1, MDC, MIG), growth and
angiogenic factors (IGF-1 and IGFBP-1), as well as anti-inflamma-
tory cytokines (IL-5) were only inhibited by chemical inhibitor (NS-
398) treatment and not by COX-2 knock-down (Table S4). These
results indicate some COX-2 independent effects of chemical
inhibitors. Growth factor EGF, anti-inflammatory cytokine IL-10,
regulators of MMP activity like TIMP-1 and TIMP-2 were up-
regulated by COX-2 inhibition (group 3) (Table S4).
Figure5.Effect ofNS-398orCOX-2silencingonKSHVinfectioninduced cytokinegeneexpression. Histogramsdepictthefoldinductionin
gene expression of KSHV infected, or NS-398 pretreated for 1 h and then infected with KSHV, or si-COX-2-2-HMVEC-d/si-C-HMVEC-d cells infected with
30DNAcopies/ cellofKSHVfor4 h, 8 h,and24 h.IL-8(A),VEGF-A(B),IL-1b (C),SDF-1(D). The%inhibitionwascalculated byconsideringcytokinegene
expression in the infected cells at the respective time of measurement as 100%. Each reaction was done in quadruplicate, and each bar represents the
average 6 SD of four independent experiments. *,**, ***-statistically significant at p,0.01, p,0.005 and p,0.001 respectively.
doi:10.1371/journal.ppat.1000777.g005
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A and VEGF-C secretion
Over-expression of COX-2 is known to correlate with the
aggressive and invasive potential of tumor cells by several
mechanisms [32]. One of the mechanisms modulated by COX-2
during carcinogenesis is angiogenesis, presumably through in-
creased production of the most potent and extensively studied pro-
angiogenic factor, VEGF [45]. Here, we examined the role of
KSHV induced COX-2 in the secretion of two angiogenic factors,
VEGF-A and VEGF-C. VEGF-A is a dimeric glycoprotein with
structural homology to PDGF, and is known to have several
variants. We used an anti-human VEGF-A mouse monoclonal
antibody that detects all isoforms, particularly the most commonly
expressed 189, 165 and 121 amino acid splice variants. When
examined by IFA, uninfected HMVEC-d cells showed a very low
level of expression of COX-2 and VEGF-A (Figure 6A, panels a
and b). In contrast, at 24 h PI, several cells were positive for
cytoplasmic staining of COX-2 and VEGF-A (Figure 6A, panels d
and e). Co-expression of VEGF-A and COX-2 was observed in
40–50% of infected cells (Figure 6A, panel f), which demonstrated
that KSHV infection of primary endothelial cells up-regulated
expression of both VEGF-A and COX-2 simultaneously. Unin-
fected cells in close proximity to the infected cells also showed
expression of COX-2 and VEGF-A (data not shown).
Basal levels of VEGF-A (Figure 6B and 6C) and VEGF-C
(Figure 6D and 6E) secretion in uninfected non-transduced and si-
C, si-COX-2-1or si-COX-2-2transduced HMVEC-d were similar.
PretreatmentofHMVEC-d cellswitheitherNS-398orIndodidnot
have any non-specific inhibition on the basal levels of VEGF-C
secretion (Figure 6D). KSHV infectionof serum starved HMVEC-d
cells induced 1029, 1420, 2211, and 2371 pg/ml of VEGF-C
secretion at 2 h, 4 h, 8 h, and 24 h, respectively. (Figure 6D), while
1239, 1457, 1897, and 2200 pg/ml of VEGF-C secretion in serum
starved si-C-HMVEC-d cells was observed at 2 h, 4 h, 8 h, and
24 h,respectively(Figure6E).TreatmentofcellswitheitherNS-398
or Indo prior to KSHV infection reduced VEGF-A and VEGF-C
secretion at all the time points tested (Figures 6B and 6D). Analyses
showed that NS-398 pretreatment inhibited VEGF-A and VEGF-C
secretion which was higher than inhibition by Indo treatment
(Figures 6B and 6D). COX-2 silencing also inhibited VEGF-A and
VEGF-C secretion but to a lesser extent than chemical inhibitor
treatment (Figures 6B-6E). The incomplete inhibition of VEGF
secretion by COX-2 chemical inhibitors suggested that besides
COX-2, other factors induced by KSHV infection might also be
playing a role in VEGF release from infected cells.
COX-2 regulates VEGF-A gene expression and secretion
in latently infected endothelial cells
To evaluate the role of COX-2 in regulating angiogenesis in
latently infected cells, we checked the expression of VEGF-A and
VEGF-C (Figure 6F) in TIVE-LTC cells untreated or treated with
either 500 mM Indo or 75 mM NS-398 for 24 h. Compared to
TIVE cells, TIVE-LTC cells showed 9.8- and 2.4 fold higher
VEGF-A and -C gene expression, respectively (Figure 6F).
Pretreatment of TIVE-LTC cells with either Indo. or NS-398
significantly inhibited the expression of VEGF-A, clearly demon-
strating the role of COX-2 in regulating VEGF-A gene expression
in latently infected cells (Figure 6F). Similar to VEGF-A gene
expression, TIVE-LTC cells secreted appreciably high levels of
VEGF-A (54 pg/ml) as compared to TIVE cells and this secretion
was effectively reduced upon treatment with COX inhibitors
(Figure 6G). VEGF-C secretion from TIVE (1800 pg/ml) and
TIVE-LTC (2200 pg/ml) cells was comparable.
KSHV induced COX-2 plays a role in KSHV infection
induced capillary tube formation of normal endothelial
cells
One important biological effect of PGE2, VEGF, and bFGF
secretion is the induction of endothelial cell tube formation. Many
chemokines are also recognized as important mediators of
endothelial cell migration and tubular organization. For a
comprehensive understanding of the role of KSHV induced
COX-2 in VEGF-related angiogenesis of infected endothelial cells,
conditioned media obtained either from serum starved (8 h)
HMVEC-d cells infected with KSHV (24 h), or cells pretreated
with COX inhibitors (Indo or NS-398) and then uninfected or
infected with KSHV (24h) were tested for their ability to induce
tube formation. Representative pictures are shown in Figure S7A.
HMVEC-d cells spontaneously organized into a primitive vascular
network even in the presence of EBM-2 alone (no serum) (Figure
S7A, panel a). This network was still observed with supernatants
from cells treated for 24h with COX-2 inhibitors which suggested
that inhibitor treatment did not have any adverse effect on the
secreted factors in the uninfected cells (Figure S7A, panels b and
c). In contrast, highly organized enhanced capillary tube
formations with strong branching networks were observed in
endothelial cells incubated with conditioned medium from cells
infected with KSHV for 24h (Figure S7A, panel d). When
supernatants from cells pretreated with COX inhibitors and then
infected with KSHV (24h) were used, we observed significant
inhibition of tube formation (Figure S7A, panels e and f). Higher
inhibition was observed with NS-398 pretreated infected cell
supernatant with complete impairment and disintegration of tube
formation (Figure S7A, panel f) which is in contrast to the strong,
well communicating tubes observed with media after 24h KSHV
infection alone (Figure S7A, panel d). These results suggested a
direct role for KSHV infection induced COX-2 in the induction of
factors mediating endothelial cell capillary tube formation.
When suramin, which possesses anti-angiogenic properties, was
used as a negative control, cells failed to adhere to each other and
remained either as single cells or clumps of cells with no tube
formation (Figure S7A, panel g). In contrast, conditioned medium
from cells cultured in the presence of medium with growth factors
(EGM-2) showed intact and organized endothelial lattice forma-
tion comparable to the network formed in the KSHV infected
culture supernatant (Figure S7A, panels h and d). This suggested a
role for GFs in tube formation. Supernatant obtained from solvent
treated and then KSHV infected cells showed a strong intact tube
network that was comparable to the one observed in the presence
of cells infected with KSHV for 24h (Figure S7A, panels d and i),
thus ruling out the possibility of non-specific inhibition by solvent
control on tube formation of endothelial cells. Similar results for
tube formation were observed with HUVEC cells (data not
shown).
The angiogenic index can be measured either by taking the sum
of all the nodes (connection between various tubes on the matrigel)
between the tubes formed on the matrigel or the length and width
of tube formation between nodes. Results represented in Figure 7A
show branch points/field, a measure of connections among cells.
Supernatants from KSHV infected cells induced the number of
branch points by about 2.5-fold as compared to EBM-2 only.
Diffused nodes with incomplete branches were not counted.
Branch points per field in the supernatants obtained from KSHV
infected cells versus cells in the presence of EGM-2 were similar.
Compared to supernatants from KSHV infected cells, superna-
tants from Indo or NS-398 pretreated and infected cells inhibited
node formation by 45% and 80%, respectively (Figure 7A).
Supernatants from cells pretreated with the solvent control before
COX-2 in KSHV Biology
PLoS Pathogens | www.plospathogens.org 13 February 2010 | Volume 6 | Issue 2 | e1000777Figure 6. Role of COX-2 in KSHV-induced VEGF-A and C. (A) Immunofluorescence analysis of COX-2 and VEGF-A expression in uninfected
HMVEC-d and KSHV infected cells (24 h PI) using COX-2 and VEGF-A specific antibodies. (B-E) Conditioned media from serum-starved uninfected
HMVEC-d cells, KSHV infected cells, cells incubated with COX-2 specific inhibitor NS-398 or non-COX isotype selective inhibitor Indo and from cells
silenced for COX-2 or lamin (control) and then infected were collected and analyzed by ELISA for the released VEGF-A (B, C) and VEGF-C (D, E)
proteins. Each reaction was done in quadruplicate, and each point represents the average 6 SD from four independent experiments. Data was
normalized to 1 mg/ml total protein concentration in the supernatant. Proteins secreted from uninfected cells were considered 1-fold. % inhibition of
VEGF-A and VEGF-C secretion was calculated by considering the release from the infected cells at the respective time of measurement as 100%. (F)
VEGF-A and VEGF-C gene expression as measured by q-RT-PCR with cDNA prepared from serum starved (24 h) TIVE-LTC cells untreated or treated
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formation and was comparable to the branch points formed in the
presence of EGM-2 or KSHV infection (Figure 7A).
A similar experiment was done for si-C, si-COX-2-1 and si-
COX-2-2 transduced HMVEC-d (Figure S7B) and HUVEC cells.
Transduction with si-C, si-COX-2-1 or si-COX-2-2 did not have
any non-specific effects on the secretion of factors involved in
angiogenesis (Figure S7B, panels a, b, and c). Tube formation in
medium obtained from si-C transduced cells (Figure S7B, panel a)
was comparable to the results from non-transduced uninfected
cells (Figure S7A, panel a). Tube formation in the presence of
medium obtained from infected si-COX-2-1 (Figure S7B, panels e
and f) or si-COX-2-2 transduced cells (Figure S7B, panels h and i)
was diminished, and nodes were diffuse compared to supernatants
from infected si-C-HMVEC-d cells (Figure S7B, panels d and g).
Consistent with the COX-2 inhibitor data, silencing by either si-
COX-2-1 or si-COX-2-2 in endothelial cells prior to KSHV
infection also reduced the ability of supernatants to induce node
formation by approximately 22% and 24%, respectively, com-
pared to si-C-HMVEC-d cells infected for 24h (Figure 7B). This
inhibition was less pronounced when compared to the huge
reduction (80%) observed with the supernatants in the presence of
NS-398. Similar results for tube formation were observed with
HUVEC cells (data not shown) implying that COX-2 plays an
important role in regulating the angiogenic phenotype of KSHV
infected endothelial cells.
COX-2 regulates angiogenesis and capillary tube
formation in latently infected endothelial cells
As TIVE-LTC cells showed high VEGF-A gene expression and
secretion, to further assess the biological role of secreted angiogenic
factors, an endothelial cell tube formation assay was performed
(Figure S8). HMVEC-d cells were seeded on a Matrigel-coated 96-
well plate with conditioned medium obtained from 24h serum
starved TIVE (Figure S8, panels 1–4), or TIVE-LTC cells (Figure
S8, panels 5–8). After 16h of incubation with conditioned media,
plates were examined for capillary-like tubular structures as
described before. HMVEC-d cells spontaneously organized into a
primitive vascular network even in the presence of medium
obtained from TIVE cells (Figure S8, panels 1–4). Highly organized
and intricate capillary tube formations with strong branching
networkswereobservedincellsincubatedwithconditionedmedium
obtained from TIVE-LTC cells (Figure S8, panels 5–8). This
network was also observed in the presence of solvent treated TIVE-
LTC cells (Figure S8, panels 9–12), ruling out the possibility of non-
specific inhibition by solvent on tube formation. In contrast, with
supernatants from TIVE-LTC cells pretreated with COX inhibi-
tors, we observed significant inhibitionof tube formation(Figure S8,
panels 13–20). Higher inhibition was observed with NS-398 treated
TIVE-LTC cell supernatant which had complete impairment of
tube formation (Figure S8, panels 17–20).
Quantitatively, supernatant obtained from TIVE-LTC cells
induced roughly 3-fold more branch points/field than TIVE cells
(Figure 7C). Pretreatment of TIVE-LTC cells with either Indo or
NS-398 inhibited the secretion of angiogenic factors and thereby
reduced node formation by 49% and 85%, respectively (Figure 7C).
Together, these results suggest that KSHV induced COX-2 not
only mediates the expression of growth and angiogenic factors from
latently infected endothelial cells butalsotheir functional properties,
such as angiogenesis related tube formation.
KSHV infection induces the secretion of various MMPs
and TIMPs
MMPs belong to a family of secreted or membrane-associated
zinc endopeptidases capable of digesting connective tissue ECM
proteins as well as basement membrane constituents [46], and
have been shown to play a critical role in orchestrating cell
signaling, homeostasis of the extracellular environment via
proteolysing their specific substrates [47], cell-cell and cell-matrix
interactions, maintaining tight junctions, and thereby contributing
to the malignant phenotypes of cancers, including cell invasion,
metastasis, angiogenesis and inflammatory infiltration. So far, 23
MMPs have been identified in humans, and based largely on their
substrate specificity, these are divided into collagenase like MMPs
(21, 28, 213), gelatinase like MMPs (22, 29), stromelysin or
proteoglycanase like MMPs (23, 27, 210, 211), elastase (-12),
membrane type-MMPs (1–4), and unclassified MMPs. Among
them, MMP-2 and MMP-9 are known to be strongly correlated
with the metastatic potential of cancer cells and in particular are
prognostic factors in many solid tumors [46,48]. MMP
(21,22,27,29,213) and MT-MMP-14 expression has been
shown by immunohistochemistry in AIDS-related and classic
cutaneous KS lesions at various histologic stages [49] implicating
them in KS tumorigenesis and invasion. Here, we assessed the role
of KSHV induced COX-2 on MMPs in uninfected and KSHV
infected HMVEC-d cells.
Conditioned media collected from serum starved (8h) uninfect-
ed or KSHV infected HMVEC-d cells were used to probe for the
presence of various MMPs and TIMPs using MMP antibody
arrays (Figure 8A). Conditioned media from the uninfected cells
had appreciable amounts of MMP-1 and -10 (Figure 8B). KSHV
infection up-regulated the secretion of MMPs and TIMPs
(Figures 8B and 8C) at all of the time points tested. Except for
MMP-3, secretion of MMPs (-1, -2, -8, -9, -10 and -13) was
enhanced in a time dependent manner with higher levels of
secretion for MMP-9 and -2 (Figure 8C).
TIMPsareendogenousinhibitorsofMMPsand the TIMPfamily
consists of four distinct members, TIMP-1, -2, -3, and -4. Among
these, TIMP-2 expression is constitutive and widely expressed
throughout the body but TIMP-1, -3, -4 expression is inducible and
often exhibits tissue specificity [46]. The balance between MMPs/
TIMPs regulates ECM turnover, regulates tumor invasion and
metastasis, wound healing and tissue remodeling during normal
development and pathogenesis. The conditioned media from
uninfected cells showed appreciable amounts of TIMPs 1 and 2
(Figures 8B and 8C). TIMP (21, 22 and 24) secretion increased
with the time post- KSHV infection (Figure 8C).
KSHV induced COX-2 regulates the MMPs in infected
endothelial cells
Effect of COX-2 inhibition was tested for a few select MMPs.
MMP (21, 22, 29 and 210) gene expression was induced during
with either 500 mM Indo or 75 mM NS-398 for 24 h. Result shows the mean 6 S.D of three independent experiments. % inhibition in gene expression
upon inhibitor treatment was calculated using gene expression in untreated TIVE-LTC cells as 100%. (G) Conditioned media from serum-starved
(24 h) TIVE-LTC cells untreated or treated with either 500 mM Indo or 75 mM NS-398 for 24 h were collected and analyzed by ELISA for the released
VEGF-A. Each reaction was done in quadruplicate, and each point represents the average 6 SD from four independent experiments. Data was
normalized to 1 mg/ml total protein concentration in the supernatant. Proteins secreted from untreated TIVE-LTC cells were considered 100%.*, **,
***-statistically significant at p,0.01, p,0.005 and p,0.001 respectively.
doi:10.1371/journal.ppat.1000777.g006
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pretreatment reduced the expression of all MMPs tested
(Figures 8D-8G), with the most significant inhibition of MMP-2
and MMP-9 (Figures 8E and 8F), suggesting that KSHV induced
COX-2 plays a decisive role in controlling expression of KSHV
infection induced proteases. Pretreatment of HMVEC-d cells with
NS-398 slightly induced the expression of TIMP-1 and TIMP-2 by
1.4- and 1.3- fold, respectively as compared to 24h PI (data not
shown). This data also supported the cytokine antibody array data
(Table S4), where pretreatment of cells by NS-398 up-regulated
the release of TIMP-2 by 2.1 fold at 24 h PI.
COX-2 regulates MMPs in latently infected endothelial
cells
To evaluate the role of COX-2 in regulating angiogenesis and
invasion, we checked the expression of MMP-9 and MMP-2
(Figure 8H) in TIVE-LTC cells treated with either 500 mM Indo
or 75 mM NS-398 for 24 h. Compared to TIVE cells, TIVE-LTC
cells showed nearly 4.5 and 5.7-fold higher MMP-2 and MMP-9
gene expression, respectively (Figure 8H). Pretreatment of TIVE-
LTC cells with either inhibitor for 24h significantly inhibited the
expression of MMP-9 and MMP-2, clearly demonstrating the role
of COX-2 in gene expression during KSHV latency (Figure 8H).
KSHV induced COX-2 regulates the activity of MMPs in
de-novo infected and latently infected endothelial cells
Since the antibody array data presented in 8A-8C measured the
total MMP pool (sum of inactive and active) secreted, we next used
an MMP-9 ELISA to differentiate between the levels of the active
form of the enzyme from the total released MMP-9. Compared to
uninfected cells, about 2, 2.3, and 3.8-fold induction in the release
of total MMP-9 was observed at 4h, 8h, and 24h PI (Figure 9A)
which was consistent with the antibody array data (Figures 8B and
8C). NS-398 treatment prior to infection inhibited total as well as
active-MMP-9 secretion implicating the role of KSHV induced
COX-2 in regulating MMP-9 (Figure 9A). Similar to chemical
blocking, compared to si-C HMVEC-d cells, COX-2 depletion by
si-COX-2 (2) significantly decreased, total as well as active, MMP-
9 secretion (Figure 9B). Compared to TIVE cells, about 2.8-fold
and 2.1-fold induction in the release of total MMP-9 and active-
MMP-9 was observed in TIVE-LTC cells (Figure 9C). COX
inhibitor treatment of TIVE-LTC inhibited total as well as active-
MMP-9 secretion (Figure 9D), indicating the importance of COX-
2 in regulating MMP-9.
A similar analysis was performed for total and active-MMP-2.
In agreement with MMP-antibody array data, we observed a 3.3,
3.3, and 3.5-fold induction in total MMP-2 release at 4h, 8h, and
24h PI (Figures 9E and 9F). NS-398 pretreatrment decreased the
secretion of total MMP-2 but not that of active MMP-2
(Figure 9E). COX-2 depletion did not effectively inhibit either
total or active MMP-2 induced by KSHV (Figure 9F). Latently
infected TIVE-LTC cells demonstrated roughly about 1.8 and 1.5-
fold induction in the release of total and active-MMP-2 as
compared to TIVE cells (Figure 9G). Similar to total MMP-2
secretion, COX inhibition also regulated the secretion of active-
MMP-2 and this activity was reduced in the cells treated with NS-
398 (35%) or Indo (34%) for 24h (Figure 9H).
KSHV infection induced COX-2 augments endothelial cell
invasion and functions through both autocrine and
paracrine mechanisms
To assess the functionality of active MMP secretion upon
KSHV infection, we performed invasion assays as described in the
Figure 7. Effect of COX-2 inhibition on KSHV infection-induced
capillary tube formation in normal HMVEC-d cells. (A and B)
Quantitative representation for branch points/field in the presence of
supernatants obtained from HMVEC-d cells treated with COX-2
inhibitors or solvent control, or cells pretreated with COX-2 inhibitors
and then infected (24 h) or cells silenced for COX-2 and then infected
for 24h. Percent inhibition was calculated by considering the branch
points/field observed in the presence of KSHV infected supernatant or
the supernatant obtained from infected si-C-HMVEC-d as 100%.
***-statistically significant at p,0.001. (C) Quantitative representation
for branch points/field in the presence of conditioned medium
obtained from 24 h serum starved TIVE cells and COX-2 inhibitors or
solvent pretreated or untreated TIVE-LTC cells. Percent inhibition was
calculated by considering the branch points observed in the absence of
COX inhibitor treatment in TIVE-LTC cells as 100%. Fold increase in the
branch points/field was calculated considering branch points/field in
presence of TIVE cell supernatant as 1 fold.
doi:10.1371/journal.ppat.1000777.g007
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PLoS Pathogens | www.plospathogens.org 16 February 2010 | Volume 6 | Issue 2 | e1000777Figure8. KSHV induced COX-2 regulates MMP gene expression in HMVEC-d as well as latently infected endothelial cells. (A) Scheme of
MMPs on MMP array-1. (B) Representative MMP arrays showing the signals for various MMPs in the conditioned medium obtained from serum starved
uninfected HMVEC-d cells or cells infected with 30 DNA copies/ cell of KSHV for 4 h, 8 h, and 24 h. (C) Densitometric analysis of MMP array blots
measuring the release of human MMPs. The values were normalized to identical background levels using the Ray Biotech Human MMP antibody array 1
analysis tool. The fold induction in MMP secretion was calculated by dividing the respective values obtained from infected-cell supernatants with the
values obtained from uninfected-cell supernatants. Each point represents the average 6 SD from three independent experiments. (D, E, F and G)M M P
gene expression. MMP-1 (D), MMP-2 (E), MMP-9 (F), and MMP-10 (G) gene expression was measured by q-RT-PCR with cDNA prepared from serum
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Innocyte cell invasion assay while Figures S9 and S10 represent the
invasive potential of the supernatants (used in Figures 9I-9L) as
analyzed by Chemicon cell invasion assay. Similar results were
obtained from both the methods used.
To evaluate the effect of KSHV infection on cell invasion, we
infected HMVEC-d cells with KSHV at 30 DNA copies/ cell. At
24h PI, we assayed the ability of the cells to invade the ECMatrix
barriers. Without chemoattractant gradients, the intrinsic inva-
siveness of normal HMVEC-d cells through an ECMatrix barrier
was undetectable (data not shown). However, in the presence of
complete growth medium as chemoattractant, some normal
HMVEC-d cells succeeded in invading the ECMatrix barrier
(Figure S9B; panel 1). KSHV-infected cells displayed increased
invasiveness that was 4.5-fold higher than uninfected (169 cells/
field versus 43 cells/field) (Figure S9B; panels 2 and 1). In contrast,
NS-398 pretreated and then KSHV-infected cells showed reduced
(68%) invasiveness (52 cells/field versus 169 cells/field) (Figure
S9B; panels 4 and 2). This reduction in invasiveness was due to
COX-2 inhibitor pretreatment rather than a non-specific effect of
the NS-398 solvent as invasiveness in the solvent treated and
infected cells was similar to that of cells infected with KSHV alone
(164 cells/field versus 169 cells/field) (Figure S9B; panels 3 and 2).
To demonstrate whether KSHV infection could promote cell
invasion in a paracrine fashion, we assessed the invasiveness of
normal HMVEC-d cells in the presence of supernatants from
uninfected- or KSHV-infected HMVEC-d cells. KSHV infection
increased HMVEC-d cell invasiveness by 3-fold (47 versus 112
cells/field), 3.5-fold (52 versus 158 cells/field) and 3.5-fold (54
versus 180 cells/field) at 4h, 8h, and 24 h, respectively (Figures 9J
and S9C; panels 1–3 versus 4–6). NS-398 pretreatment reduced
KSHV promotion of cell invasion by 50% (77 versus 112 cells/
field), 70% (43 versus 158 cells/field), and 70% (48 versus 180
cells/field) after 4, 8, and 24h, respectively. This indicated that
KSHV induced COX-2 plays a critical role in regulation of MMPs
and associated invasion (Figures 9J and S9C; panels 4–6 versus 7–
9). Supernatant obtained from solvent pretreated infected cells was
similar to KSHV infected cell culture supernatant (data not
shown). Similar to NS-398 pretreatment, COX-2 silencing also
reduced KSHV promotion of cell invasion (Figure 9K). This
further validated the role of KSHV induced COX-2 in cell
invasion, and suggests that KSHV infection could promote COX-
2-dependent cell invasion through both autocrine and paracrine
mechanisms. HT1080 cells showed maximum invasion (Figure
S9C, panel 10).
KSHV infection induced COX-2 regulates invasion of TIVE-
LTC cells
Latently infected TIVE-LTC cells (169 cells/field) (Figures 9L
and S10; panels 3 and 4) showed 3-fold increased invasiveness
compared to TIVE cells (57 cells/field) (Figures 9L and S10;
panels 1 and 2). This suggested that KSHV infection mediated
secretion of proteases must be contributing to the invasive
phenotype of TIVE-LTC cells. NS-398 pretreatment for 24h
reduced TIVE-LTC cell invasion by 63% (62 cells/field versus
169 cells/field) (Figures 9L and S10; panels 7 and 8 versus 3 and
4) whereas Indo pretreatment reduced invasiveness by 43% (96
cells/field versus 169 cells/field) (Figures 9L and S10; panels 5
and 6 versus panels 3 and 4). Solvent treatment did not have any
effect on TIVE-LTC cell invasion (176 cells/field versus 169
cells/field) (Figures 9L and S10; panels 9 and 10 versus panels 3
and 4) further validating the specific regulation of invasion by
COX-2.
KSHV infection induced PGE2 secretion regulates
endothelial cell adhesion
COX-2 expression and PGE2 secretion has been shown to
accelerate integrin dependent cell adhesion, migration and cell-
spreading [50]. Progression of KS from early stage to an invasive
and metastatic phenotype is accompanied by a series of changes
associated with cytoskeleton rearrangements as well as alterations
in cell-cell and cell-matrix adhesion that allows cells to invade
surrounding tissues and metastasize. To understand the role of
KSHV induced COX-2 in the adhesion of endothelial cells, an
adhesion assay was done using untreated maxisorp plates or plates
coated with polylysine or fibronectin. Adhesion in the presence of
polylysine was interpreted as the result of interaction between the
polyanionic cell surfaces and the polycationic layer of adsorbed
polylysine and reflective of charge based interactions rather than a
response to secreted factors or surface expression of various
integrins. Adhesion in the presence of fibronectin was interpreted
as the result of interaction with integrins as it is an extracellular
matrix glycoprotein that binds to integrins. Since we observed
maximum PGE2 secretion during primary infection at 2h PI [26],
we collected supernatants at 2h PI to demonstrate the paracrine
role of PGE2 in the presence or absence of drug and used to test
their ability to induce adhesion of uninfected cells. Conditioned
medium collected during later time points of infection representing
latency were not used for these assays.
Endothelial cells were allowed to adhere in the presence of the
culture supernatant obtained from uninfected endothelial cells (2h)
or the cells infected with KSHV for 2h, or cells pretreated with
NS-398 for 1h and then infected with KSHV for 2h. Previously,
we have shown that pretreatment of HMVEC-d cells with NS-398
inhibited the secretion of PGE2, suggesting that these supernatants
would be depleted of PGE2. When plated on untreated plates,
compared to the adhesion of cells in the presence of supernatant
from uninfected cells, adhesion of uninfected HMVEC-d cells
increased in the presence of culture supernatant from KSHV
infected endothelial cells (Figure 10A). Treatment of the plate
surface with polylysine increased the kinetics of binding irrespec-
tive of the presence of various culture supernatants (Figure 10B).
When plated on fibronectin coated plates, cell adhesion kinetics
were faster in the presence of infected cell culture supernatant
suggesting a role for paracrine factors in the expression of integrins
and its interaction with the integrin ligand, fibronectin
(Figure 10C).
To address the role of PGE2 in HMVEC-d cell adhesion, we
plated the cells in the presence of serum free medium containing
1 mM PGE2 which markedly enhanced HMVEC-d adhesion to
the untreated as well as fibronectin coated plates (Figures 10A and
10C). The adhesion kinetics on the fibronectin plates was faster
starved (8h) HMVEC-d cells infected or NS-398 treated (1h), and then infected with KSHV for 4h, 8h, and 24h. Result shows the mean 6 S.D of three
independent experiments. % inhibition in gene expression upon NS-398 treatment was calculated using gene expression in the presence of KSHV
infected HMVEC-d cells at different time points as 100%. (H) MMP-2 and MMP-9 gene expression in TIVE-LTC cells upon COX inhibitor treatment. Gene
expression was measured by q-RT-PCR with cDNA prepared from serum starved (24h) TIVE-LTC cells untreated or treated with either 500 mMI n d oo r
75 mM NS-398 for 24h. Result shows the mean 6 S.D of three independent experiments. % inhibition in gene expression upon inhibitor treatment was
calculated using gene expression in untreated TIVE-LTC cells as 100%. *, **, ***-statistically significant at p,0.01, p,0.005 and p,0.001 respectively.
doi:10.1371/journal.ppat.1000777.g008
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PLoS Pathogens | www.plospathogens.org 18 February 2010 | Volume 6 | Issue 2 | e1000777Figure 9. Effect of COX-2 inhibition on activity of MMPs and invasion of de novo infected HMVEC-d and latently infected TIVE-LTC
cells. (A) Activation of MMP-9 measured by the MMP-9 assay kit in uninfected HMVEC-d cells, untreated KSHV infected, uninfected NS-398 treated or
NS-398 pretreated and then infected with KSHV for 4h, 8h, and 24h. Total MMP-9 reflects the pool of pro-form and active form of MMP-9 whereas
active MMP-9 exclusively represents the active protease. % inhibition of MMP-9 levels (total or active) upon NS-398 treatment was calculated
considering MMP-9 levels (total or active) in the presence of KSHV infected HMVEC-d at different time points as 100%. (B) Activation of MMP-9 in the
uninfected (4h, 8h, and 24h), KSHV infected (4h, 8h, and 24h) si-C-HMVEC-d and si-COX-2-HMVEC-d cells. % inhibition of MMP-9 levels (total or active)
in si-COX-2-HMVEC-d were calculated considering MMP-9 levels (total or active) in KSHV infected si-C-HMVEC-d at different time points as 100%. (C)
Similarly, activation of MMP-9 in conditioned medium obtained from 24h serum starved TIVE and TIVE-LTC cells was performed. The levels of total
and active MMP-9 in TIVE cells were considered 1 fold for comparison. (D) Activation of MMP-9 in the TIVE-LTC untreated or treated with 500 mM Indo
or 75 mM NS-398 for 24h. % inhibition in these protease levels (total or active) upon COX inhibition was calculated considering MMP-9 levels (total or
active) in untreated TIVE-LTC cells as 100%. (E-H) Activation of MMP-2 was measured in the conditioned media described in A-D using an MMP-2
assay kit. Method of estimation and analysis was similar to A-D. COX-2 regulates KSHV infected HMVEC-d cell invasion via autocrine and
paracrine mechanisms. (I) Effect of KSHV infection and COX-2 regulation upon the invasive potential of endothelial cells was measured by a
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coated plates, PGE2 increased cell adhesion to the untreated and
fibronectin coated plates suggesting its role in regulating the
expression of surface molecules, possibly integrins or adhesion
molecules, on the endothelial cells to facilitate rapid adhesion.
To understand the role of COX-2 inhibition and abrogated
secretion of PGE2 in endothelial cell adhesion, we used the
supernatant obtained from the cells pretreated with NS-398 and
then infected with KSHV. Adherence of cells in the presence of
NS-398 treated KSHV infected culture supernatant was compar-
atively less on all plates (untreated, fibronectin coated and
polylysine coated) (Figures 10A-C) but decreased appreciably in
the fibronectin coated plates (Figures 10A and 10C). This further
confirmed the critical role of KSHV induced COX-2/PGE2 in
endothelial cell adhesion. The role of PGE2 secretion in
endothelial cell adhesion was further confirmed by using culture
supernatants from KSHV infected si-C-, si-COX-2-1 or si-COX-
2-2 -HMVEC-d cells (Figures 10D-F). Adhesion on untreated
plates or fibronectin coated plates was reduced significantly in the
presence of supernatants from si-COX-2-1 and -2 and KSHV
infected HMVEC-d cells when compared to si-C-infected
HMVEC-d cells (Figures 10D-F). This confirmed the involvement
of KSHV infection induced COX-2/PGE2 in cell adhesion.
Effects were more pronounced on fibronectin coated plates
suggesting that COX-2/PGE2 mediates endothelial cell integrin
expression or modulation of cell adhesion molecules. These results
clearly demonstrated that COX-2/PGE2 play pivotal roles in cell
adhesion to the matrix, an important event in KSHV pathogenesis
that has seen little exploration.
KSHV-PGE2 regulated endothelial cell adhesion involves
Rac1 activation
Rearrangement of the actin cytoskeleton is primarily controlled
by members of the Rho-GTPase family such as RhoA, Rac1, and
Cdc42 [51]. Our earlier studies have demonstrated the activation
of these GTPases by KSHV infection and stimulation by
interaction of the KSHV envelope glycoprotein gB with adherent
endothelial or fibroblast cell integrins [25,35,52]. RhoA-GTPases
are implicated in regulating morphology and adhesion because
interactions between the actin cytoskeleton and adherens junctions
determine cell shape and motility [51]. RhoA and Rac have been
shown to be critical regulators of cell adhesion and cell spreading
while COX-2/prostaglandin production has been reported to be
essential for integrin-dependent Rac activation in HUVEC cells
[53]. Hence, we assessed the role of KSHV infection induced
PGE2 in regulating these signaling molecules.
First, we asked the question whether secreted factors participate
in the activation of RhoA- or Rac-GTPases. We quantified the
RhoA-GTPase activity using a RhoA-GLISA kit on the lysates
prepared from cells grown on untreated plates for different time
points in the presence of culture supernatants from serum starved
(8 h) uninfected HMVEC-d (2 h) and KSHV infected (2 h) cells.
We observed 3.4, 3.9, 3.8 and 4.5-fold RhoA-GTPase activation
upon plating cells in the presence of infected cell culture
supernatant for 159,3 0 9,4 5 9 and 609, respectively (Figure 10G).
This data suggested that the factors released during KSHV
infection up-regulated RhoA-GTPase in the adhering cells.
Next, to understand the role of PGE2 in the regulation of
RhoA-GTPase activity of infected cells, we tested the lysates from
cells plated on untreated plates for 309 in the presence of
supernatant from cells uninfected or infected for 2h, and cells
pretreated with 50 mM NS-398 for 1h and then infected with
KSHV for 2h. Supernatant from the cells pretreated with NS-398
moderately inhibited activation of RhoA-GTPase (Figure 10G)
suggesting that PGE2 secretion might not be involved in the
stimulation of RhoA in HMVEC-d cell adherence. Activation of
RhoA-GTPase was also measured in the lysate from cells grown in
the presence of PGE2 for 309. Induction of RhoA was ,50%
lower when compared to RhoA-GTPase activity in the presence of
infected cell culture supernatant. This suggested that PGE2 alone
is not enough to induce RhoA-GTPase in adherence of endothelial
cells. Similar results were obtained from lysates prepared from cells
plated on fibronectin coated plates thus ruling out the possibility of
PGE2 participation in the interaction of integrins modulating
RhoA-GTPase activity (Figure 10G).
AsRac-GTPasesalsoplayanimportantrole incellspreadingand
cell adhesion, we analyzed the activation kinetics of Rac1 by Rac1-
GLISA. We observed 2.7, 3.8, 4.4 and 4.2- fold Rac1-GTPase
activation upon plating cells in the presence of infected cell culture
supernatant for 159,3 0 9,4 5 9 and 609, respectively. This data
suggested that the factors released during KSHV infection up-
regulated Rac1-GTPase in adherent endothelial cells. Supernatant
prepared from cells pretreated with NS-398 drastically (65%)
inhibited Rac1-GTPase activation (Figure 10H) suggesting that
PGE2 secretion is involved in the stimulation of Rac1 in endothelial
cells. To further confirm the role of PGE2, activation of Rac1-
GTPasewasmeasuredinthelysatepreparedfromcellsgrowninthe
presence of PGE2 for 309. Induction of Rac1-GTPase was 4.8- fold
when compared to Rac1-GTPase activity in the presence of
uninfected cell culture supernatant suggesting that PGE2 is enough
to induce Rac1-GTPase in the adhering endothelial cells. Similar
results were obtained from lysates prepared from cells plated on
fibronectin coated plates thus demonstrating the possibility that
fluorescence based invasion assay as described in Materials and Methods. Fluoresence intensity is presented and the values shown are the mean6
S.D of three independent experiments. % Inhibition in invasion by NS-398 treatment was calculated considering invasion in the presence of KSHV
infection as 100%. Fold induction in invasion upon KSHV infection was calculated by considering invasion of the uninfected cells as 1 fold. (J)
Invasion of HMVEC-d cells in the presence of supernatant from treated HMVEC-d cells. Histogram represents the fluorescence intensity
(mean6 S.D of three independent experiments) of HMVEC-d cells invaded in the presence of conditioned media obtained from uninfected, KSHV
infected, uninfected NS-398 treated, NS-398 pretreated and then KSHV infected for 4 h, 8 h and 24 h. HT1080 cells were used as positive control and
were allowed to invade for 24 h. % Inhibition in invasion upon NS-398 treatment was calculated considering invasion in the presence of KSHV
infection at the indicated time point as 100%. Fold increase in invasion upon KSHV infection was calculated by considering invasion in the presence
of medium from uninfected cells at the same time as 1 fold. (K) Histogram represents the fluorescence intensity of HMVEC-d cells invaded in the
presence of conditioned media obtained from uninfected, KSHV infected si-C-HMVEC-d and si-COX-2-HMVEC-d cells at 4 h, 8 h and 24h. % Inhibition
of invasion in si-COX-2-HMVEC-d cells was calculated considering invasion in the presence of si-C-HMVEC-d cells at indicated time points as 100%.
Fold increase in invasion upon KSHV infection in si-C-HMVEC-d cells was calculated by considering invasion in the presence of medium from
uninfected si-COX-2-HMVEC-d cells at the same time as 1 fold. (L) Effect of COX-2 inhibition on invasion of TIVE, TIVE-LTC cells in the
presence of COX inhibitors. The invasive cells were dislodged from the underside of the cell culture insert and stained with a fluorescent dye in a
single step and fluorescence was determined using a fluorimeter as described before. Fluorescence associated with the invaded cells is shown and
the values correspond to the mean6 S.D of three independent experiments. Fold increase in the invasion of TIVE-LTC cells was calculated using the
invasive potential of TIVE cells as 1 fold. *, **, ***-statistically significant at p,0.01, p,0.005 and p,0.001 respectively.
doi:10.1371/journal.ppat.1000777.g009
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PLoS Pathogens | www.plospathogens.org 20 February 2010 | Volume 6 | Issue 2 | e1000777Figure 10. Measurement of endothelial cell adhesion. HMVEC-d cells were allowed to adhere on untreated (A, D), polylysine (B, E), or
fibronectin (C, F) coated plates in the absence or presence of culture supernatants obtained from uninfected HMVEC-d cells (2 h), KSHV infected
(2 h), NS-398 treated and then KSHV infected cells, or in the presence of serum free medium containing PGE2 (A, B and C) and adhesion kinetics
were done at the indicated time points. A similar experiment was done using the supernatants obtained from uninfected or infected (2 h) si-C-
HMVEC-d, si-COX-2 (1)-HMVEC-d, or si-COX-2 (2)-HMVEC-d cells (D, E and F). Adhered cells were photographed (pictures not shown). Unattached
cells were removed by washing and attached cells were fixed using 4% paraformaldehyde at the indicated times and visualized by crystal violet
staining. Results are provided as optical density (O.D.) and represent the mean of triplicate determinations 6 S.D. (G and H) Histograms representing
RhoA-GTPase (G) or Rac1-GTPase (H) activation in HMVEC-d cells in the presence of various supernatants (as mentioned in results) for the indicated
time points on either untreated or fibronectin coated plates and measured by GLISA. Fold activation of RhoA and Rac1 is calculated by considering
RhoA or Rac1-GTPase activity in the presence of uninfected cell culture supernatant as 1 fold. Each reaction was done in triplicate, and each bar
represents the mean 6 S.D. for three experiments. (I, J and K) Representative gels depicting Rac1-GTPase activation in HMVEC-d cells plated in the
presence of various supernatants (as mentioned in results) for indicated time points on either untreated or fibronectin coated plates and measured
using a PAK pull-down assay. Fold change of Rac1 activation is calculated by determining the band intensities and are expressed as fold increase over
the cells plated in the presence of uninfected culture supernatant taken as 1- fold. Each blot is representative of a minimum of three separate
experiments. **, ***-statistically significant at p,0.005 and p,0.001 respectively.
doi:10.1371/journal.ppat.1000777.g010
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GTPase activity (Figure 10H).
Rac1 activity was further confirmed using a PAK pull-down
assay and fold activation was calculated by considering the Rac1-
GTPase activity in the presence of uninfected supernatant at 609
as one fold. About 1.8, 2, 3 and 2.5- fold activation of Rac1-
GTPase was observed at 159,3 0 9,4 5 9, and 609, respectively
(Figure 10I). Supernatant from the cells pretreated with NS-398
and then infected inhibited Rac1 by 75% (Figure 10J, lanes 3 and
1). This suggested that PGE2 secretion plays an important role in
Rac1 stimulation, which was further supported by the 2.4-fold
activity of Rac1 in the lysates prepared from cells plated in the
presence of PGE2 alone for 309 (Figure 10J, lane 4) which was
comparable to the activity observed in the presence of infected cell
culture supernatant (Figure 10J, lane 4). HMVEC-d cells plated on
fibronectin coated plates cultured in the presence of the
supernatant obtained from the 2h infected cell showed 2.5-fold
activation of Rac1 which was completely abrogated (100%
inhibition) in the presence of supernatant prepared from NS-398
pretreated and then infected endothelial cells (Figure 10K, lanes
1–3). Stimulation of Rac1 activity in PGE2 stimulated HMVEC-d
cells grown on fibronectin plates was comparable to the activity
observed in the presence of infected cell culture supernatant
(Figure 10K, lanes 3 and 4). Collectively, these results clearly
demonstrated that KSHV induced COX-2/PGE2 in the infected
cell microenvironment plays an important role in endothelial cell
adhesion by modulating the activity of Rac1-GTPases.
KSHV infection induced COX-2 regulates growth of TIVE-
LTC cells
NSAIDs and derivatives of COXIBs are well documented for
their anti-neoplastic activities such as inhibition of cancer cell line
growth as well as initiation and promotion of apoptosis in various
cancers [54]. Since KSHV induced COX-2 has an important role
in regulation of viral latent gene expression that is linked to
prolonged host cell survival, we assessed the effect of long term
incubation of COX inhibitor (up to 96h) in latently infected
endothelial cells (TIVE-LTC). To obtain the normal growth curve,
cells were cultured in growth medium for 24 h, 48 h, 72 h, and
96 h before an MTT assay was performed. Results shown in
Figure 11A depict growth kinetics of both cell types under normal
conditions which clearly indicate that at any given time TIVE-LTC
cells grow much faster than TIVE cells (Figure 11A). We next
determined whether the longer duration of COX inhibitor
treatment should be given in the presence of complete growth
medium conditioned with serum or under serum starvation. Under
serum deprivation, both cell types show reduced proliferation and
the control TIVE cells appeared to be particularly dependent on
serum growth factors for viability. This suggested that KSHV in
TIVE-LTC cells must be inducing the secretion of growth factors
that help target cell survival (Figure 11A). Even though the MTT
assay measures mitochondrial activity in viable and in growth-
arrested cells, its dynamic range is limited and can only be taken as
an indicator for initial changes in cell survival. Therefore, we used
traditional viable cell counting in similar experiments (Figure 11A).
TIVE LTC cells displayed faster growth kinetics than TIVE cells
thus validating the data obtained with the MTT assay (Figure 11A).
Although, TIVE-LTC cells did not show profound death upon
serum deprivation, TIVE cell viability was reduced by 8%, 32%
and 66% at 48 h, 72 h and 96 h, respectively (Figure 11B). This
further demonstrated the role of KSHV in secretion of various
growth factors required for cell survival.
Next, we examined the effect of COX inhibitors on metabolism
and growth index in latently infected cells. Neither fresh growth
medium nor additional drug was added during the observation
period for MTT and trypan blue exclusion assays. In MTT assays,
we observed significant inhibition of TIVE-LTC cell metabolic
activity with both drugs at all time points tested and the inhibition
was marginally more with Indo for 72 h and 96 h (Figure 11C).
Treatment for the same duration with solvent alone did not inhibit
the metabolic activity of these cells (Figure 11C) thus validating the
specific effect of COX inhibition. Similar to the MTT assay, we
observed that treatment of TIVE-LTC cells with Indo reduced cell
viability by 6%, 37%, 41% and 55% at 24 h, 48 h, 72 h, and 96 h
(Figure 11D) while NS-398 treatment reduced cell viability by 4%,
11%, 31%, and 42% at 24 h, 48 h, 72 h, and 96 h, respectively
(Figure 11D). It should be noted that TIVE and TIVE-LTC cells
have hTERT which has been shown to be regulated by COX
inhibitors [55]. To rule out the possibility that reduced cell
viability and decreased cell metabolic activity observed in TIVE-
LTC cells is not because of hTERT modulation of KSHV gene
expression and related events in pathogenesis, we assessed the role
of drug treatment for longer duration on the control TIVE cells
(Figures 11E and 11F). NS-398 treatment did not reduce the
metabolic activity of TIVE cells (Figure 11E), whereas Indo
treatment affected TIVE cell metabolic activity only marginally,
by about 9% and 15% at 48h and 72h of incubation, respectively
(Figure 11E). Similarly, Indo treatment reduced TIVE cell viability
only by 2% and 11% at 48h and 72h, respectively (Figure 11F).
Since longer incubation (48h, 72 and 96h) with the COX
inhibitors reduced cell viability as observed by MTT assay, we
assessed the effect of the COX inhibitor treatments on cell cycle
profiling of TIVE and TIVE-LTC cells (Figure 11G, S11). To
determine whether growth inhibition by COX inhibitors was
attributable to cell cycle arrest, TIVE-LTC cells were treated with
and without COX inhibitors for 24–96 h. According to the DNA
profile, a significantly higher proportion of untreated TIVE-LTC
cells were in S-phase compared to either Indo or NS-398 treated
cells over longer incubation periods (48–96 h). We observed a clear
anti-proliferative shift in the profile of the cell cycle parameters
towards a reduced percentage of cells at the S and G2/M phases,
together with an increased percentage of cells at the G1 phase.
Approximately 70% reduction in S phase was observed in cells
treated with COX inhibitors for 96 h (Figure 11G). There was not
much change in the G2/M phase but in the drug treated cells, there
was subsequent cell accumulation in the G0/G1 phase suggesting
that COX inhibitors inhibit latently infected cells from crossing the
G1/S boundary. Similar results were obtained with NS-398
treatment but solvent treatment did not affect the cell cycle profile
of TIVE-LTC cells (data not shown) further validating the specific
effect of the drug used for treatment. As 24 h treatment of TIVE-
LTC cells with COX inhibitors could reduce ORF73 gene
expression, we also assessed the long term effect of these drug
treatments on KSHV latent gene expression. We observed 75–80%
reduction in ORF73 gene expression in these cells after 96 h
incubation with drugs (data not shown). Compared to TIVE–LTC,
untreated TIVE cells showed shorter S phase (14%) and these cells
were not affected by COX inhibitor treatment even after longer
incubations (data not shown). These observations clearly suggest
that COX-2 inhibitor treatment for longer durations slows
proliferation of virally infected cells accompanied by reduced viral
latent gene expression and thereby subsequently reducing the
secretion of growth factors required for infected cell survival.
Discussion
KS, a chronic inflammation associated tumor, is the most
common aggressive malignancy among untreated HIV-infected
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PLoS Pathogens | www.plospathogens.org 22 February 2010 | Volume 6 | Issue 2 | e1000777Figure 11. Effect of COX-2 inhibition on cell survival and cell cycle profile of latently infected TIVE-LTC cells. (A, C and E) COX inhibition
reduces TIVE-LTC cell proliferation. MTT assay results shown in each panel represent the absorption at 570 nm with TIVE or TIVE-LTC cells. Cells were
incubated in the presence or absence of serum or presence of 500 mMI n d o ,7 5mM NS-398, or solvent control for 24 h-96 h. (B, D and F) COX regulates
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endothelial origin, neovascular structures and inflammatory cells,
is believed to be profoundly driven by the autocrine and paracrine
loops of ICs, GFs and angiogenic factors present in the lesion
microenvironment [2]. Hence, to effectively control and eliminate
KS lesions, it is very important to understand the driving forces
behind the initiation and maintenance of these secreted factors.
KSHV latent gene expression observed in KS endothelial cells and
the lytic gene expression observed in a limited percentage of KS
inflammatory cells probably contributes to the up-regulation of
cellular host factors and a synergy between host and viral factors
could be contributing to the sustained induction of inflammatory
molecules and progression of lesions. Our study unravels the
multifactorial complexity of KSHV-host interactions governing
KS progression/pathogenesis in conjunction with host factor
COX-2 and its inflammatory metabolite PGE2 (Figure 12). The
exhaustive studies presented here demonstrate that COX-2/PGE2
induction upon KSHV infection is an excellent example of synergy
between host and viral factors, where COX-2 operates like a
central player and performs dual functions of controlling
downstream consequences of KSHV infection as well as latent
viral gene expression. COX-2 not only helps maintain an
angiogenic and inflammatory cytokine rich KSHV permissive
microenvironment but also sustains viral latent gene expression
critical for infected cell survival. Our findings also suggest the
potential for COX-2 inhibition based therapies in treating angio-
proliferative KS lesions as COX-2 silencing, as well as treatment
with COX-2 chemical inhibitors, could effectively reduce
inflammation, angiogenesis, cell adhesion, cell invasion and cell
signaling events during KSHV de novo and latent infection.
Our study illustrates a continuous loop of events where COX-2
behaves like an intermediate in controlling KSHV pathogenesis
and latency. However, the mechanism behind sustained COX-2
protein levels and tight regulation of its activity is still missing in
this loop. Attractive answer to this question would be the interplay
of viral proteins or, PGE2 per se or sustained levels of secreted
factors or signal molecules like NF-kB [56]. Studies are underway
to understand the transcriptional and post-transcriptional regula-
tion of COX-2 during KSHV infection.
Role of KSHV induced COX-2/PGE2 in viral pathogenesis
Expression of COX-2 in KS lesions, the detection of higher
levels of PGE2 in KS tissue compared to surrounding normal
tissue [57], significant over-expression of COX-2 in the early
inflammatory/angiogenic stage as well as in the late nodular stage
of classic and epidemic forms of KS lesions [58], together with our
studies demonstrating COX-2 in KS lesions (skin tissue and lymph
node), endothelial cells infected for 5 days and latently infected
endothelial cells (TIVE-LTC) (Figures 1 and 2) emphasizes that
prostaglandin cascade components are actively involved in KS
pathogenesis and strengthens the role of COX/PGE2 in KSHV
biology. Fold inductions for COX-2 and m-PGES-1 in HMVEC-d
(5d inf.) cells with about 50–60% infection and TIVE-LTC cells
expressing LANA in 50–60% of the cells were comparable. Our
data demonstrate that 50–60% of TIVE-LTC cells were ORF73
positive and these cells were also positive for COX-2. In addition,
COX-2 staining was also seen in the cells in close proximity to the
uninfected cells which could be due to paracrine COX-2
stimulation by growth factors induced upon KSHV infection.
This study for the first time systematically evaluated the
downstream consequences of KSHV induced COX-2/PGE2 by
using COX-2 inhibition strategies involving parallel chemical
inhibition and gene silencing approachs. This study also illustrates
that cytokine secretion upon KSHV infection is not a random
event but follows tightly regulated kinetics (Figure 4 and Table S3).
It also indicates that inhibition of cytokines via inhibitor treatment
is highly selective (Figure 5 and Table S4). For example, levels of
IFN-c, MCP-2, MCP-3, TARC, GCP-2, MIP-3a, Eotaxins, CK-
b8-1, PDGF-BB, MCSF, G-CSF, GMCSF, angiogenin, VEGF,
SDF-1, SCF, TGF-b1, leptin, and ILs (-3, -4 and -15) could be
inhibited either by treatment with COX-2 inhibitor or NF-kB
inhibitor [56]. Cytokines, like ILs (25, 26 and 210) and GRO-a,
were strongly inhibited by NF-kB inhibition, but not by COX-2
inhibition. In contrast, IL-1a, IL-1b, IL12-p40, TNF-a, IP-10,
NAP-2, Oncostatin M, thrombopoeitin, FGFs (24, 26, 27 and
29), Flt3-ligand, Fractalkine, IGFBPs and Osteoprotegerin were
strongly inhibited by COX-2 inhibitor pretreatment demonstrat-
ing the specificity of downstream pathways regulated via COX-2
and NF-kB. Interestingly, KSHV infection induces sustained levels
of NF-kB [56]. This, together with the fact that PGE2 itself can
activate NF-kB, suggests the potential involvement of the COX-2-
NFkB-COX-2/PGE2 axis during KSHV infection. Treatment of
infected endothelial cells with Indo or NS-398 reduced the nuclear
translocation of p65 (an indication of NF-kB activity) by 46% and
58%, respectively (data not shown), which suggests the involve-
ment of COX-2/NF-kB in regulation of secreted factors. COX-2
inhibition could not impair cytokine secretion by 100%, which
suggests the importance of viral and other host factors in
controlling these cytokines.
To establish a lifelong successful infection in an immunocom-
petent host, KSHV must be utilizing an impressive array of
immune modulatory mechanisms, one of which appears to be the
induction of COX-2/PGE2. For example, the ability of COX-2/
PGE2 to mediate regulation of IFN and RANTES (Table S4),
involved in the recruitment of inflammatory cells, represents one
strategy which KSHV utilizes to evade the host immune system.
KSHV induced COX-2/PGE2 also regulates VEGF-A and
VEGF-C (Figure 6), the multifunctional potent immunosuppres-
sive cytokines that profoundly regulate cell growth, adhesion,
angiogenesis, proliferation and differentiation, as well as FGF-4,
PDGF, TGF-b, IL-1b and IL-6 which are known to up-regulate
VEGF expression. Interestingly, increased COX-2 mRNA
expression and PGE2 secretion has been shown to enhance
VEGF mRNA expression suggesting a direct role for PGE2 in
stimulation of angiogenesis [59]. VEGF-C and –A are also known
to induce lymphangiogenesis and play key roles in lymphatic
reprogramming involving the conversion of blood endothelial cells
(BEC) to lymphatic endothelial cells (LEC) [60]; an important
event in KS pathogenesis. In addition, reduced levels of IL-3
(Table S4), a known inducer of lymphatic markers Prox-1 and
podoplanin in HMVEC-d cells, by COX-2 inhibition delineates a
very significant role of COX-2 in KSHV lymphangiogenesis [61].
VEGF-A was found to be tightly regulated by COX-2/PGE2 in
de novo infected HMVEC-d and TIVE-LTC cells (Figure 6).
cell viability in TIVE-LTC cells. Panels show the number of viable cells using a trypan blue exclusion assay. TIVE or TIVE-LTC cells were incubated in the
presence or absence of serum in the presence of 500 mM Indo or 75 mM NS-398, or solvent control for 24 h-96 h. (G) Comparative effects of
indomethacin and NS-398 on the proliferative profile of TIVE-LTC cells. Cell sorter analysis was performed using TIVE-LTC cells cultured in the
presence and absence of indicated drugs. Propidium iodide staining of untreated, 500 mM Indo or 75 mM NS-398 treated TIVE-LTC cells was done for 24 h-
96 h. The percentages of cells at specific cell-cycle phases are indicated and the numbers represent mean values of six independent experiments.
doi:10.1371/journal.ppat.1000777.g011
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PLoS Pathogens | www.plospathogens.org 24 February 2010 | Volume 6 | Issue 2 | e1000777Similar to the involvement of COX-2/PGE2 in cytokine secretion
in many inflammation related diseases [62], KSHV induced
COX-2 also plays important roles in the expression and secretion
of various chemokines, growth and angiogenic factors and thereby
controls the angiogenesis and tube formation (Figure 7, S7, and
S8) events of KS pathogenesis.
COX-2 has been implicated in invasiveness, angiogenesis and
distant metastases of many cancers [63]. MMP secretion has been
associated with many viruses, including EBV [64,65,66], hepatitis
B virus (HBV) [67] and HIV-1 [68]. However, little is known
about the functional role of MMPs and TIMPs in KSHV infection
and KS. Our studies report for the first time the role of KSHV
induced MMP-2 and MMP-9 (Figure 8) secretion in HMVEC-d
and latently infected TIVE-LTC cells. HMVEC-d cell MMP
secretion kinetics was different from the published kinetics in
HUVEC cells [12], which could be due to cell type specific
patterns of MMP secretion. TIVE-LTC cells secreted diminished
levels of MMP-2 when compared to de novo infected cells
(Figure 9E and 9G), therefore COX-2 inhibition could not
effectively down-regulate active MMP-2 secretion during de novo
infection (Figure 9E and 9F) compared to TIVE-LTC cells.
Higher active-MMP-2 levels even upon COX-2 inhibitor
Figure 12. Schematic diagram depicting the multiple outcomes of KSHV induced COX-2 in endothelial cells, consequences and role
in pathogenesis. In vitro KSHV infection of HMVEC-d cells involves binding of the virus to the cell surface heparan sulfate (HS) molecules via its
envelope glycoproteins gpK8.1A and gB [26,34,35,52], followed by interaction with integrins and xCT molecules. Virus interaction with target cell
triggers pre-existing signal cascades facilitating virus entry, delivery of viral genome into the target cell nucleus and reprograms host gene expression
required for various growth, angiogenic and invasive factors and one which being COX-2 [26]. Data presented here show appreciable COX-2 gene
expression at 5d PI of endothelial cells, in latently infected TIVE-LTC cells and in KS lesions. COX-2 catalyzes the synthesis of PGH2 from arachidonic
acid (AA) through an unstable intermediate PGG2 [26]. PGH2 is converted by mPGES to PGE2, which is released to the infected cell supernatant where
it can mediate its downstream effects through either an autocrine or paracrine mechanism on a neighboring infected or uninfected cell via their
interactions through the family of seven transmembrane G-protein-coupled rhodopsin-type EP (1–4) receptors. KSHV induced COX-2 regulates
multiple events involved in KS pathogenesis such as secretion of pro-inflammatory cytokines, growth and angiogenic factors, anti-inflammatory
cytokines, and MMPs and TIMPs. In addition, COX-2 induction also regulated infection related cell adhesion to the ECM, invasion through the matrix
and angiogenesis related capillary tube formation. We demonstrated that KSHV infection induced COX-2/PGE2 also stimulates the induction of Rac1-
GTPases in adhering endothelial cells. Interestingly, our study also demonstrates that KSHV infection induced COX-2 potentially modulates the
survival and proliferation of latently infected endothelial cells. In summary, together with the down-regulation of viral latent gene expression upon
COX-2 inhibition, our study suggests that KSHV hijacks host cellular machinery and manipulates cellular inducible angiogenic stress response gene
COX-2 to its advantage to aggravate pathogenesis, cell survival and its persistence in the target cell.
doi:10.1371/journal.ppat.1000777.g012
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factors other than COX-2/PGE2 or the inhibitor dose was
insufficient to regulate its secretion. COX-2 inhibition specifically
abrogated the expression and secretion of MMP-9 (9A-9D) in de
novo infected as well as latently infected endothelial cells, a
protease responsible for metastatic potential and triggering the
angiogenic switch [16]. COX-2/PGE2 probably regulates MMP-9
at the transcriptional level by activating transcription factors like
AP-1, Ets2, NF-kB, and Sp1 [33]. MMP-9 has the potential to
increase VEGF release, its bioavailability to bind to VEGF
receptors on endothelial cells, and thus leading to an angiogenic
loop that eventually will result in cell migration, cell proliferation
and angiogenesis [69]. COX-2 might be a key player regulating
many feedback loops in cytokine-MMP interactions, including
chemokines such as RANTES, TNF-a, GM-CSF and SDF-1
which induce MMP-9 that can cleave a spectrum of pro-cytokines
like TNF-a, pro-TGFb and IL-1b. COX-2 levels could modulate
multifunctional TIMP-1 and -2, which can inhibit MMP activities
and can activate the FAK/PI3-K or Src/PI3-K pathways [70,71].
Along with the other above mentioned functions, PGE2 released
early (2 h) during infection also enhanced the kinetics of
endothelial cell adhesion (Figure 10). Increased adhesion could
be attributed to various crucial factors controlled by PGE2, such as
the activation of Rac1-GTPases (Figure 10), release of SDF-1 [72],
IL-1b, TNF-a, along with the cell surface expression of adhesion
molecules and integrins like aVb3 and b1 [53]. Collectively, our
study underscores the importance of the COX-2-PGE2-MMP-9
axis in KS pathogenesis and suggests that COX-2 inhibitors have
tremendous therapeutic potential in KSHV biology.
Role of COX-2/PGE2 in establishment of viral latency
Many viruses, such as herpes simplex virus (HSV), human
cytomegalovirus (HCMV), pseudorabies virus (PRV), human
herpesvirus-6 (HHV-6), EBV, murine herpesvirus 68 (MHV-68),
and human T-cell leukemia virus type 1 (HTLV-1), have been
shown to induce COX-2 and release PGE2 that participate in viral
lytic replication. In contrast, the role of COX-2/PGE2 in KSHV
infection appears to be different as our previous [26] and current
studies demonstrate that COX-2/PGE2 not only regulates
inflammation associated events via modulating cytokine secretion
but also controls viral latency (Figure 2E) which has been shown to
be essential for viral genome maintenance and host cell survival
[23,73].
COX-2 has been shown to play direct roles in the enchance-
ment of tumorigenic and angiogenic factors in KSHV indepen-
dent cancers. However, COX-2 appears to play an additional
unique role in the context of KS pathogenesis and in creating a KS
lesion microenvironment rich in cytokines since it also participates
in KSHV biology by virtue of its ability to aid in the establishment
and maintenance of latent gene expression. Since KSHV latent
genes themselves are shown to be powerful mediators of anti-
apoptosis, cell survival, as well as gene regulation including the
induction of COX-2 and other cytokines and angiogenic factors
[37,56], our study exposes an interesting regulatory loop between
KSHV induction of COX-2 expression, COX-2’s role in the
establishment and maintenance of KSHV latency and the
induction of cytokines and angiogenic factors that sustains the
KSHV-permissive microenvironment. Hence the observed effect
of COX-2 inhibition on cytokines, angiogenesis and cell survival in
the context of KSHV infected cells is probably not just due to
COX-2’s role as the direct activator of these processes but
probably due to the combinatorial effect on reduction in KSHV
latent gene expression and its downstream consequences including
reduction in COX-2 expression, and cell survival. The observed
regulatory loop of COX-2 in KSHV biology opens up a new
avenue that could be potentially exploited for an effective control
of KSHV and KS lesions.
Besides overcoming host intrinsic, innate and adaptive immune
responses, survival of latently infected cells requires the constant
blockage of apoptosis. Intriguingly, we observed that COX-2/
PGE2 is involved in regulating latently infected TIVE-LTC cell
survival (Figure 11). COX-2 inhibition for longer duration could
shorten S phase, arrest TIVE-LTC cells at G1/S phase
accompanied by further lowered ORF73 gene expression
(Figure 11G and S11). An important question to be answered is
whether exogenous supplementation of PGE2 in cells treated with
COX-2 inhibitors will rescue cells from undergoing death or cell
cycle arrest. Nevertheless, our study reveals that KSHV infection
induced COX-2/PGE2 is an important anchor linking viral gene
expression, GFs and cell survival in latently infected cells. We have
demonstrated a reduction in ORF73 gene expression at early as
well as later time points of COX-2 inhibitor treatment and a
reduction in the cells in S phase at later times of drug incubation
(Figure 11G). One of the key properties of LANA is to stimulate
cells in the S phase entry [73] by relocalizing GSK3-b and
stabilizing b-catenin, thereby manipulating the GSK3b-b-catenin
complex. Decreased ORF73 gene expression upon COX inhibitor
treatment and the shortened S phase of latently infected cells raises
the possibility that COX inhibition might be disturbing the ability
of LANA to interact with GSK-3b and the Rb protein required for
G1/S progression. In other words KSHV might be utilizing COX-
2 and PGE2 to stabilize these complexes required for successful
latency. ORF73 gene expression is also critical to overcome the
host chromatin-binding protein BRD4-and BRD2/RING3-stim-
ulated G1/S arrest [74], therefore reduced ORF73 gene
expression upon COX-2 inhibition could be pushing the cells to
G1/S arrest.
This study also raises important questions including the role of
COX-2/PGE2 in viral episome maintenance and their effects on
LANA protein levels. As PGE2 is known to stimulate several
signaling events (JNK-1, ERK1/2, PKC, PI3K-AKT, HPK1,
Src), second messengers including cAMP, calcium and reactive
oxygen species (ROS), and modulate various transcription factors
(Ets-1, Sp1, Oct-1, STAT-3, AP-1, ELK-1, hypoxia inducible
factor-1a, and b-catenin) [75,76,77,78,79,80,81,82,83,84,85,86,
87,88,89], COX-2/PGE2 could be mediating their effect on
KSHV latency via one or more of these factors. It is interesting to
note that some of the PGE2 activated transcription factors (Sp1,
HIF-1a and AP-1) are well established for their role in modulation
of viral latency (ORF73) and lytic (ORF50) promoters [90,91,92].
Studies to decipher the molecular pathway of PGE2 mediated
ORF73 promoter regulation and viral latency is under investiga-
tion. The ability of KSHV to utilize pro-inflammatory molecules
to maintain latent gene expression demonstrates the plasticity of
the KSHV genome and its adaptability to host surveillance.
Currently, there are no methods available to eliminate the latent
infection of herpesviruses. Slow proliferation of KSHV latently
infected cells accompanied by reduced viral latent gene expression
upon treatment with COX-2 inhibitors (Figure 11) strongly
demonstrates that COX-2 is an excellent target for controlling
KSHV latency.
At present, two classes of COX inhibitors are currently available
for use in humans. NSAIDs inhibit both COX-1 and COX-2
while COXIBs are COX-2 selective with very little effect on
COX-1 and consequently have been described as ‘‘healthier,
dedicated, and more targeted’’ [93]. Despite a few COX-
independent actions [43] of chemical inhibitors, these are still
the most promising drugs for treating inflammation associated
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mitogenic and anti-angiogenic compounds. Observations such as
reduced b-FGF and VEGF secretion and MMP-9 regulation
reveals that COX-2 inhibitors possess the potential to be exploited
in the in vivo model to better understand their benefits as an
adjuvant to the currently available chemotherapy for KS.
Interestingly, PGE2 has also been shown to modulate several
functions associated with rapamycin, a drug shown to be
efficacious against PEL cell lines [94]. COX-2 inhibitors show
additive effects when used as part of a combination therapy since
they potentiate the effect of IFN-a in HCV infection [95] and
IFN-c in several tumors [96,97]. Hence, their inclusion in
combination with KS chemotherapy, radiation, and biological
therapies might prove to be beneficial in the KS scenario. Effective
inhibition of COX-2 could lead to reduced KSHV infection of
endothelial cells which may in turn reduce the accompanying
inflammation and KS lesion progression.
Supporting Information
Figure S1 Magnified views of COX-2 and ORF73 expression in
sections shown in Figures 1A, 1C. Arrow head (black) indicates
COX-2 staining. Arrow (black) in panels 2 and 4 indicates ORF73
staining. Magnifications: 20X.
Found at: doi:10.1371/journal.ppat.1000777.s001 (10.57 MB
TIF)
Figure S2 COX-2 staining in various tissue sections on tissue
microarray. Brown color indicates COX-2 staining. Panels 1-54
represent different tissue sections on KS-TMA as mentioned. 1
(skin), 2 (small bowel), 3 (skin), 4 (mouth), 5(mouth), 6 (lymph
node), 7 (lymph node), 8 (lung), 9 (lymph node), 10 (lung), 11 (small
bowel), 12 (lymph node), 13 (lymph node), 14 (skin), 15 (eye orbit),
16 (epiglottis), 17 (lymph node), 18 (tonsil), 19 (skin), 20 (lymph
node), 21(anus), 22 (skin), 23(anus), 24 (lymph node), 25 (skin), 26
(mouth), 27 (skin), 28 (skin), 29 (skin), 30 (lymph node), 31
(nasopharynx), 32 (hypopharynx), 33 (soft tissue mass), 34 (skin), 35
(skin), 36 (skin), 37 (skin), 38 (skin), 39 (lymph node), 40 (skin), 41
(skin), 42 (lymph node), 43 (lymph node), 44 (skin), 45 (tonsil), 46
(lymph node), 47 (skin), 48 (skin), 49 (skin), 50 (spleen), 51 (skin), 52
(lymph node), 53 (lymph node), and 54 (tongue). Magnifications:
10X.
Found at: doi:10.1371/journal.ppat.1000777.s002 (8.13 MB TIF)
Figure S3 Spontaneous lytic reactivation of KSHV. HMVEC-d
cells grown to 80-90% confluence were infected with 30 DNA
copies/ cell of KSHV for 2h, 4days and 5 days, fixed and
permeabilised. Uninfected and infected cells were incubated with
ORF73 (green; Panels 1-6) and ORF59 (red; Panels 7-18) specific
antibodies, washed, incubated with secondary antibodies, washed,
counterstained with DAPI and examined under a fluorescence
microscope.
Found at: doi:10.1371/journal.ppat.1000777.s003 (4.08 MB TIF)
Figure S4 Effect of inhibitors on PGE2 secretion. Cell free
culture supernatants of TIVE-LTC untreated or treated with
indicated doses of COX inhibitors for 1h, 8h, and 24h were used
to measure the levels of PGE2 by ELISA. Each reaction was done
in duplicate, and each point represents the average 6 SD from
three independent experiments. **, *** -statistically significant at
p,0.005 and p,0.001 respectively.
Found at: doi:10.1371/journal.ppat.1000777.s004 (2.14 MB TIF)
Figure S5 (A) Representative Cytokine arrays showing the
signals for various cytokines in the conditioned medium from
serum starved HMVEC-d cells infected 30 DNA copies/ cell of
KSHV for 96h and the conditioned medium from serum starved
HMVEC-d cells infected with KSHV (30 DNA copies/ cell) for
96h that was pre-incubated with 100 mg/ml of heparin for 1h. (B)
Representative Cytokine arrays showing the signals for cytokines
in the conditioned medium from serum starved uninfected
HMVEC-d cells or cells infected for 4h with 30 DNA copies/
cell of KSHV.
Found at: doi:10.1371/journal.ppat.1000777.s005 (0.88 MB TIF)
Figure S6 (A-D) Effect of NS-398 or COX-2 silencing on
KSHV infection induced VEGF-C, GM-CSF, GRO, and
RANTES gene expression. Each histogram depicts the fold
induction in gene expression of KSHV infected, or NS-398
pretreated for 1h and then infected with KSHV, or si-COX-2-2-
HMVEC-d/si-C-HMVEC-d cells infected with 30 DNA copies/
cell of KSHV for 4h, 8h, and 24h. The % inhibition was
calculated by considering cytokine gene expression in the infected
cells at the respective time of measurement as 100%. Each
reaction was done in quadruplicate, and each bar represents the
average 6 SD of four independent experiments. *, **,
***-statistically significant at p,0.01, p,0.005 and p,0.001
respectively.
Found at: doi:10.1371/journal.ppat.1000777.s006 (2.69 MB TIF)
Figure S7 (A) Effect of COX-2 inhibition by Indo or NS-398 on
KSHV-induced uninfected HMVEC-d capillary tube formation.
Photomicrograph showing HMVEC-d cell tube formation with
various supernatants in a matrigel coated 96-well plate. (a)
endothelial basal medium; Supernatants were from: (b and c) cells
treated with inhibitors alone; (d) cells infected with KSHV for 24h;
(e) cells pretreated with Indo (500 mM,1h) and then infected with
KSHV for 24h; (f) cells pretreated with the NS-398 (50 mM,1h) and
then infected with KSHV for 24h; (g) cells pretreated with the
Suramin; (h) cells cultured in the presence of EGM-2 complete
growth medium (with serum); (i) cells pretreated with solvent
(vehicle) alone and then infected with KSHV for 24h. After 16h
incubation, plates were examined for capillary tube formation
under an inverted microscope and photographed at 10X magni-
fication. Circles represent branch points/field (connections among
cells), and the line represents length of the capillary tubes. Each
assay was done in triplicate and eachexperiment was repeated three
times and the qualitative differences were further analyzed by using
morphometric analysis in metamorph software to obtain quantita-
tive information regarding tube length. (B) Effect of COX-2
inhibition by si-RNA on KSHV-induced uninfected HMVEC-d
capillary tube formation. Photomicrograph showing HMVEC-d
cell tube formation with various supernatants in a matrigel coated
96-well plate. Supernatants were from: (a) cells silenced for lamin
(control) and then left uninfectedfor 24h; (b) cells silencedfor COX-
2usingCOX-2-1constructandthenleftuninfectedfor24h;(c):cells
silenced for COX-2 using COX-2-2 construct and then left
uninfected for 24h; (d) cells silenced for lamin construct and then
infected with KSHV for 24h; (e) cells silenced for COX-2 using
COX-2-1 construct and then infected with KSHV for 24h; (f) cells
silenced for COX-2 using COX-2-2 construct and then infected
with KSHV for 24h. (g, h and i) Additional set of observations for
treatments similar to d, e and f, respectively.
Found at: doi:10.1371/journal.ppat.1000777.s007 (8.38 MB TIF)
Figure S8 Effect of COX-2 inhibition on the ability of
supernatants obtained from latently infected TIVE-LTC cells to
form tubular network in uninfected HMVEC-d cells. Photomi-
crographs showing HMVEC-d cell tube formation with various
supernatants in a matrigel coated 24-well plate. Supernatants were
from: (1-4) 24h serum starved TIVE cells; (5-8) 24h serum starved
TIVE-LTC cells; (9-12) TIVE-LTC cells treated with solvent
control (24h); (13-16) TIVE-LTC cells treated with 500 mM Indo
COX-2 in KSHV Biology
PLoS Pathogens | www.plospathogens.org 27 February 2010 | Volume 6 | Issue 2 | e1000777(24h); (17-20) TIVE-LTC cells treated with 75 mM NS-398 (24h).
Experiment was performed and analyzed as described in Figure
S6. Panels 4, 8, 12, 16 and 20 are the same view as 3, 7, 11, 15,
and 19, respectively (viewed under UV light). In these experi-
ments, Calcein-AM loaded HMVEC-d cells were used for tube
formation.
Found at: doi:10.1371/journal.ppat.1000777.s008 (2.99 MB TIF)
Figure S9 COX-2 regulates KSHV infected HMVEC-d cell
invasion via autocrine and paracrine mechanisms. (A) Schematic
for invasion assays used; 1) innocyte cell invasion assay and 2)
Chemicon cell invasion assay. (B-C) Effect of KSHV infection and
COX-2 regulation upon the invasive potential of endothelial cells
was measured by Chemicon cell invasion assay as described in
Materials and Methods. Representative pictures of uninfected,
KSHV infected, solvent control treated and KSHV infected, NS-
398 pretreated and then infected HMVEC-d cells migrated
through the ECMatrix layer are shown. All invasion assays were
carried out over 24h as described in Materials and Methods. Each
assay was done in duplicate and each experiment was repeated
three times and analyzed by considering five fields. Representative
pictures of HMVEC-d cells invaded in the presence of conditioned
media obtained from uninfected, KSHV infected, uninfected NS-
398 treated, NS-398 pretreated and then KSHV infected for 4h,
8h and 24h.
Found at: doi:10.1371/journal.ppat.1000777.s009 (6.78 MB TIF)
Figure S10 Effect of COX-2 inhibition on invasion of latently
infected TIVE-LTC cells. Representative pictures of TIVE,
TIVE-LTC untreated, solvent control treated, 500 mM Indo, or
75 mM NS-398 treated TIVE-LTC cells migrated through the
ECMatrix layer are shown. All the invasion assays were carried
out for 24h as described in Materials and Methods. 1 and 2, 3 and
4, 5 and 6, 7 and 8, 9 and 10 are pictures from duplicate wells. All
assays were done by two methods using three independent
experiments and analyzing five fields.
Found at: doi:10.1371/journal.ppat.1000777.s010 (7.48 MB TIF)
Figure S11 Effect of COX inhibitors on the cell cycle profile of
latently infected endothelial cells. Representative pictures for cell
cycle analysis after propidium iodide staining of untreated, 500
mM Indo or 75 mM NS-398 treated TIVE-LTC cells for 24h-96h.
The percentages of cells at specific cell-cycle phases are indicated
and the numbers represent mean values of six independent
experiments.
Found at: doi:10.1371/journal.ppat.1000777.s011 (4.10 MB TIF)
Table S1 COX-2 staining in Kaposi Sarcoma tumor sections
(ACSR KS Screening TMA 09-1).
Found at: doi:10.1371/journal.ppat.1000777.s012 (0.19 MB TIF)
Table S2 Sequences of real time-primers used for cytokine gene
expression.
Found at: doi:10.1371/journal.ppat.1000777.s013 (1.98 MB TIF)
Table S3 Cytokine Profiling was done using Ray Biotech human
cytokine antibody 3.1 according to manufacturer’s instructions.
Arrays were incubated with supernatants o/n at 4uC, and then
developed. The densitometry values were substituted in analysis
tool and entire array values were normalized to the same
background level. Fold induction in cytokine levels was calculated
considering levels in uninfected supernatant as 1 -fold. Data is the
average of 3 arrays per treatment.
Found at: doi:10.1371/journal.ppat.1000777.s014 (1.97 MB TIF)
Table S4 Fold reductions upon NS-398 pretreatment before
KSHV infection or COX-2 silencing upon KSHV infection are
presented and fold reduction was calculated with respect to the
levels upon infection at the respective time point of infection.
Values in red show the fold induction in levels with respect to their
corresponding levels upon infection. Data is divided into groups 1,
2, and 3, which are represented in blue, black and red colors,
respectively. Group 1 includes the cytokines inhibited by both kind
of COX-2 inhibition (chemical as well as silencing), group 2
includes the cytokines inhibited by chemical inhibitor treatment
alone, not reduced by COX-2 knockdown, and group 3 includes
the cytokines up-regulated upon COX-2 inhibition.
Found at: doi:10.1371/journal.ppat.1000777.s015 (1.08 MB TIF)
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